{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T12:40:35Z","timestamp":1794573635172,"version":"4.9.1"},"reference-count":418,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100020206","name":"Korea Dementia Research Center","doi-asserted-by":"publisher","award":["RS-2024-00348451"],"award-info":[{"award-number":["RS-2024-00348451"]}],"id":[{"id":"10.13039\/100020206","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Recent advances in our understanding of non-cell-autonomous mechanisms in neurodegenerative diseases (NDDs) have highlighted microglial dysfunction as a core driver of disease progression. Conditions such as Alzheimer\u2019s disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson\u2019s disease (PD), and frontotemporal dementia (FTD) share features of impaired microglial phagocytosis, chronic neuroinflammation, and metabolic dysregulation. These insights have prompted new therapeutic strategies targeting microglial function and emphasized the need for reliable biomarkers to monitor disease progression and treatment response. Well-established therapeutic targets, such as triggering receptor expressed on myeloid cells 2 (TREM2), progranulin (PGRN), and sortilin (SORT1), along with emerging candidates including LILRB4, P2Y6R, TAM receptors, and neuroinflammation-related markers, are discussed alongside novel blood, cerebrospinal fluid (CSF), and imaging biomarkers. Despite notable progress, many of these biomarkers remain restricted to preclinical studies and face translational challenges due to species-specific differences, lack of standardization, and clinical heterogeneity. Emerging technologies\u2014including single-cell omics, spatial transcriptomics, and artificial intelligence (AI)-driven integration of multimodal data\u2014offer new opportunities to align biomarker profiles with evolving disease states and improve patient stratification. Building on the model of companion diagnostics (CDx) in oncology, integrating multimodal biomarker strategies holds promise for guiding personalized interventions, improving clinical outcomes, and deepening our mechanistic understanding of microglial contributions across the neurodegenerative spectrum.<\/jats:p>","DOI":"10.1186\/s13024-025-00867-4","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T12:47:01Z","timestamp":1752151621000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["Biomarkers and therapeutic strategies targeting microglia in neurodegenerative diseases: current status and future directions"],"prefix":"10.1186","volume":"20","author":[{"given":"Min-Young","family":"Noh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyuk Sung\u00a0","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Soo","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minyeop","family":"Nahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Kyung","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-sung","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9644-9598","authenticated-orcid":false,"given":"Seung Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"867_CR1","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1172\/JCI58644","volume":"122","author":"RM Ransohoff","year":"2012","unstructured":"Ransohoff RM, Brown MA. Innate immunity in the central nervous system. J Clin Invest. 2012;122:1164\u201371.","journal-title":"J Clin Invest"},{"key":"867_CR2","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1002\/glia.22575","volume":"61","author":"JI Alvarez","year":"2013","unstructured":"Alvarez JI, Katayama T, Prat A. Glial influence on the blood brain barrier. Glia. 2013;61:1939\u201358.","journal-title":"Glia"},{"key":"867_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1126\/science.aat0473","volume":"362","author":"NJ Allen","year":"2018","unstructured":"Allen NJ, Lyons DA. Glia as architects of central nervous system formation and function. Science. 2018;362:181\u20135.","journal-title":"Science"},{"key":"867_CR4","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41392-023-01588-0","volume":"8","author":"C Gao","year":"2023","unstructured":"Gao C, Jiang J, Tan Y, Chen S. Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets. Signal Transduct Target Ther. 2023;8:359.","journal-title":"Signal Transduct Target Ther"},{"key":"867_CR5","doi-asserted-by":"publisher","first-page":"790","DOI":"10.3389\/fimmu.2019.00790","volume":"10","author":"DA Galloway","year":"2019","unstructured":"Galloway DA, Phillips AEM, Owen DRJ, Moore CS. Phagocytosis in the Brain: Homeostasis and Disease. Front Immunol. 2019;10:790.","journal-title":"Front Immunol"},{"key":"867_CR6","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.1016\/j.neuron.2022.10.020","volume":"110","author":"RC Paolicelli","year":"2022","unstructured":"Paolicelli RC, Sierra A, Stevens B, Tremblay ME, Aguzzi A, Ajami B, Amit I, Audinat E, Bechmann I, Bennett M, et al. Microglia states and nomenclature: A field at its crossroads. Neuron. 2022;110:3458\u201383.","journal-title":"Neuron"},{"key":"867_CR7","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/nn.4338","volume":"19","author":"RM Ransohoff","year":"2016","unstructured":"Ransohoff RM. A polarizing question: do M1 and M2 microglia exist? Nat Neurosci. 2016;19:987\u201391.","journal-title":"Nat Neurosci"},{"key":"867_CR8","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2019101997","volume":"38","author":"V Stratoulias","year":"2019","unstructured":"Stratoulias V, Venero JL, Tremblay ME, Joseph B. Microglial subtypes: diversity within the microglial community. EMBO J. 2019;38: e101997.","journal-title":"EMBO J"},{"key":"867_CR9","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1007\/s12272-022-01406-1","volume":"45","author":"MS Kwon","year":"2022","unstructured":"Kwon MS. Advanced therapeutic strategies targeting microglia: beyond neuroinflammation. Arch Pharm Res. 2022;45:618\u201330.","journal-title":"Arch Pharm Res"},{"key":"867_CR10","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41593-019-0566-1","volume":"23","author":"J Marschallinger","year":"2020","unstructured":"Marschallinger J, Iram T, Zardeneta M, Lee SE, Lehallier B, Haney MS, Pluvinage JV, Mathur V, Hahn O, Morgens DW, et al. Lipid-droplet-accumulating microglia represent a dysfunctional and proinflammatory state in the aging brain. Nat Neurosci. 2020;23:194\u2013208.","journal-title":"Nat Neurosci"},{"key":"867_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa1211851","volume":"368","author":"R Guerreiro","year":"2013","unstructured":"Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, et al. TREM2 variants in Alzheimer\u2019s disease. N Engl J Med. 2013;368:117\u201327.","journal-title":"N Engl J Med"},{"key":"867_CR12","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41577-023-00837-1","volume":"23","author":"M Colonna","year":"2023","unstructured":"Colonna M. The biology of TREM receptors. Nat Rev Immunol. 2023;23:580\u201394.","journal-title":"Nat Rev Immunol"},{"key":"867_CR13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41593-021-00975-6","volume":"25","author":"M Xie","year":"2022","unstructured":"Xie M, Liu YU, Zhao S, Zhang L, Bosco DB, Pang YP, Zhong J, Sheth U, Martens YA, Zhao N, et al. TREM2 interacts with TDP-43 and mediates microglial neuroprotection against TDP-43-related neurodegeneration. Nat Neurosci. 2022;25:26\u201338.","journal-title":"Nat Neurosci"},{"key":"867_CR14","doi-asserted-by":"publisher","first-page":"12164","DOI":"10.1096\/fj.201900992R","volume":"33","author":"Y Guo","year":"2019","unstructured":"Guo Y, Wei X, Yan H, Qin Y, Yan S, Liu J, Zhao Y, Jiang F, Lou H. TREM2 deficiency aggravates alpha-synuclein-induced neurodegeneration and neuroinflammation in Parkinson\u2019s disease models. FASEB J. 2019;33:12164\u201374.","journal-title":"FASEB J"},{"key":"867_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.795036","volume":"12","author":"XX Li","year":"2021","unstructured":"Li XX, Zhang F. Targeting TREM2 for Parkinson\u2019s Disease: Where to Go? Front Immunol. 2021;12: 795036.","journal-title":"Front Immunol"},{"key":"867_CR16","doi-asserted-by":"publisher","first-page":"873","DOI":"10.3233\/ADR-230025","volume":"7","author":"DA Loeffler","year":"2023","unstructured":"Loeffler DA. Antibody-Mediated Clearance of Brain Amyloid-beta: Mechanisms of Action, Effects of Natural and Monoclonal Anti-Abeta Antibodies, and Downstream Effects. J Alzheimers Dis Rep. 2023;7:873\u201399.","journal-title":"J Alzheimers Dis Rep"},{"key":"867_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","volume":"79","author":"S Salloway","year":"2022","unstructured":"Salloway S, Chalkias S, Barkhof F, Burkett P, Barakos J, Purcell D, Suhy J, Forrestal F, Tian Y, Umans K, et al. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease. JAMA Neurol. 2022;79:13\u201321.","journal-title":"JAMA Neurol"},{"key":"867_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12377","volume":"9","author":"LS Honig","year":"2023","unstructured":"Honig LS, Barakos J, Dhadda S, Kanekiyo M, Reyderman L, Irizarry M, Kramer LD, Swanson CJ, Sabbagh M. ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer\u2019s disease. Alzheimers Dement (N Y). 2023;9: e12377.","journal-title":"Alzheimers Dement (N Y)"},{"key":"867_CR19","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207919","volume":"102","author":"SJ Loomis","year":"2024","unstructured":"Loomis SJ, Miller R, Castrillo-Viguera C, Umans K, Cheng W, O\u2019Gorman J, Hughes R, Budd Haeberlein S, Whelan CD. Genome-Wide Association Studies of ARIA From the Aducanumab Phase 3 ENGAGE and EMERGE Studies. Neurology. 2024;102: e207919.","journal-title":"Neurology"},{"key":"867_CR20","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14:535\u201362.","journal-title":"Alzheimers Dement"},{"key":"867_CR21","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","volume":"87","author":"CR Jack Jr","year":"2016","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, Hampel H, Jagust WJ, Johnson KA, Knopman DS, et al. A\/T\/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87:539\u201347.","journal-title":"Neurology"},{"key":"867_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/alz.054615","volume":"17","author":"R Paul","year":"2021","unstructured":"Paul R, Jackson S, Ward M, Joshi A, Castro A, Yeh FL, Liao Y, Morrison G. INVOKE-2: A phase 2 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of AL002 in participants with early Alzheimer\u2019s disease. Alzheimer\u2019s & Dementia. 2021;17: e054615.","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"867_CR23","unstructured":"Baseline Characteristics for INVOKE-2: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating AL002 in Early Alzheimer\u2019s Disease. https:\/\/investors.alector.com\/static-files\/2f05cf85-8deb-4755-9cb8-6e6a0f8e3d04."},{"key":"867_CR24","doi-asserted-by":"crossref","unstructured":"Martin Stangel DF, Derya Shimshek, Fabrizio Gasparini, Ivan Galimberti, Nathalie George, Gisela Peraus, and Judit Sovago: VHB937, a TREM2 Stabilizing and Activating Antibody Strongly Reduces Pathology After Peripheral Administration in a Broad Range of Animal Models for Neuroinflammation and Neurodegeneration (P4\u20134.004). Neurology 2024.","DOI":"10.1212\/WNL.0000000000205610"},{"key":"867_CR25","unstructured":"Christian Mirescu: Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD\/PD 2024. https:\/\/investors.vigilneuro.com\/news-releases\/news-release-details\/vigil-announces-oral-presentation-small-molecule-trem2-agonist."},{"key":"867_CR26","doi-asserted-by":"publisher","first-page":"3582","DOI":"10.1212\/WNL.98.18_supplement.3582","volume":"98","author":"D Maslyar","year":"2022","unstructured":"Maslyar D, Paul R, Long H, Rhinn H, Tassi I, Morrison G, Yeh F, Schwabe T, Ward M. A Phase 1 Study of AL003 in Healthy Volunteers and Participants with Alzheimer\u2019s disease (P5\u20133.002). Neurology. 2022;98:3582.","journal-title":"Neurology"},{"key":"867_CR27","unstructured":"J.Y.C. Chan YGH, 1 C.M. Powell,1 D.L. Cooper1: ASPIRE-FTD: A Phase 1\/2 Clinical Trial to Evaluate AVB-101 in FTD with GRN mutations (FTD-GRN). ISFTD, Amsterdam, 2024 (https:\/\/aviadobio.com\/wp-content\/uploads\/2024\/09\/ISFTD-2024_AVB-Trial-Design_DIGITAL_FINAL_04Sep2024-1.pdf)."},{"issue":"4651\u20134668","key":"867_CR28","volume":"184","author":"T Logan","year":"2021","unstructured":"Logan T, Simon MJ, Rana A, Cherf GM, Srivastava A, Davis SS, Low RLY, Chiu CL, Fang M, Huang F, et al. Rescue of a lysosomal storage disorder caused by Grn loss of function with a brain penetrant progranulin biologic. Cell. 2021;184(4651\u20134668): e4625.","journal-title":"Cell"},{"key":"867_CR29","doi-asserted-by":"crossref","unstructured":"Amy Chang Berger IC, Mohammad Jafarnejad, Chi-Lu Chiu, Akhil Bhalla, Lorna Damo, Niraj M Shanbhag, Arthur Simen, Hong Lu, Stephen Zicha, Martin Bednar, Matthew D. Troyer, Carole Ho, Richard Tsai: Safety and pharmacokinetics of single ascending doses ofTAK-594\/DNL593, a brain-penetrant progranulin replacementtherapy, in healthy volunteers: Interim results from Part A of aPhase 1\/2 clinical trial. Alzheimer\u2019s & DementiaVolume 19: Drug Development 2023.","DOI":"10.1002\/alz.075068"},{"key":"867_CR30","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1186\/s12967-023-04251-y","volume":"21","author":"M Kurnellas","year":"2023","unstructured":"Kurnellas M, Mitra A, Schwabe T, Paul R, Arrant AE, Roberson ED, Ward M, Yeh F, Long H, Rosenthal A. Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementia. J Transl Med. 2023;21:387.","journal-title":"J Transl Med"},{"key":"867_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12452","volume":"10","author":"M Ward","year":"2024","unstructured":"Ward M, Carter LP, Huang JY, Maslyar D, Budda B, Paul R, Rosenthal A. Phase 1 study of latozinemab in progranulin-associated frontotemporal dementia. Alzheimers Dement (N Y). 2024;10: e12452.","journal-title":"Alzheimers Dement (N Y)"},{"key":"867_CR32","unstructured":"Alector I: Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial. ISFTD 2024, Amsterdam, The Netherlands."},{"key":"867_CR33","doi-asserted-by":"crossref","unstructured":"Rosenberg JB, Kaplitt MG, De BP, Chen A, Flagiello T, Salami C, Pey E, Zhao L, Ricart Arbona RJ, Monette S, et al. AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer\u2019s Disease. Hum Gene Ther Clin Dev. 2018;29:24\u201347.","DOI":"10.1089\/humc.2017.231"},{"key":"867_CR34","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/ana.25775","volume":"88","author":"RS Turner","year":"2020","unstructured":"Turner RS, Hebron ML, Lawler A, Mundel EE, Yusuf N, Starr JN, Anjum M, Pagan F, Torres-Yaghi Y, Shi W, et al. Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer\u2019s Disease. Ann Neurol. 2020;88:183\u201394.","journal-title":"Ann Neurol"},{"key":"867_CR35","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.3233\/ADR-240089","volume":"8","author":"ML Gordon","year":"2024","unstructured":"Gordon ML, Christen E, Keehlisen L, Gong M, Lam F, Giliberto L, Gomar JJ, Koppel J. An Open-Label, Pilot Study of Daratumumab SC in Mild to Moderate Alzheimer\u2019s Disease. J Alzheimers Dis Rep. 2024;8:1111\u20134.","journal-title":"J Alzheimers Dis Rep"},{"key":"867_CR36","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1001\/jamaneurol.2023.2851","volume":"80","author":"A Genge","year":"2023","unstructured":"Genge A, van den Berg LH, Frick G, Han S, Abikoff C, Simmons A, Lin Q, Patra K, Kupperman E, Berry JD. Efficacy and Safety of Ravulizumab, a Complement C5 Inhibitor, in Adults With Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. JAMA Neurol. 2023;80:1089\u201397.","journal-title":"JAMA Neurol"},{"key":"867_CR37","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S1474-4422(23)00378-2","volume":"23","author":"A McGarry","year":"2024","unstructured":"McGarry A, Rosanbalm S, Leinonen M, Olanow CW, To D, Bell A, Lee D, Chang J, Dubow J, Dhall R, et al. Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2024;23:37\u201345.","journal-title":"Lancet Neurol"},{"key":"867_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-047993","volume":"11","author":"N Vijiaratnam","year":"2021","unstructured":"Vijiaratnam N, Girges C, Auld G, Chau M, Maclagan K, King A, Skene S, Chowdhury K, Hibbert S, Morris H, et al. Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson\u2019s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The \u2018Exenatide-PD3\u2019 study. BMJ Open. 2021;11: e047993.","journal-title":"BMJ Open"},{"key":"867_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12158","volume":"7","author":"H Potter","year":"2021","unstructured":"Potter H, Woodcock JH, Boyd TD, Coughlan CM, O\u2019Shaughnessy JR, Borges MT, Thaker AA, Raj BA, Adamszuk K, Scott D, et al. Safety and efficacy of sargramostim (GM-CSF) in the treatment of Alzheimer\u2019s disease. Alzheimers Dement (N Y). 2021;7: e12158.","journal-title":"Alzheimers Dement (N Y)"},{"key":"867_CR40","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1080\/13543784.2023.2263357","volume":"32","author":"T Muller","year":"2023","unstructured":"Muller T. DNL151, DNL201, and BIIB094: experimental agents for the treatment of Parkinson\u2019s disease. Expert Opin Investig Drugs. 2023;32:787\u201392.","journal-title":"Expert Opin Investig Drugs"},{"key":"867_CR41","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.omtn.2017.08.002","volume":"8","author":"HT Zhao","year":"2017","unstructured":"Zhao HT, John N, Delic V, Ikeda-Lee K, Kim A, Weihofen A, Swayze EE, Kordasiewicz HB, West AB, Volpicelli-Daley LA. LRRK2 Antisense Oligonucleotides Ameliorate alpha-Synuclein Inclusion Formation in a Parkinson\u2019s Disease Mouse Model. Mol Ther Nucleic Acids. 2017;8:508\u201319.","journal-title":"Mol Ther Nucleic Acids"},{"key":"867_CR42","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2217\/nmt-2021-0022","volume":"11","author":"CL Reading","year":"2021","unstructured":"Reading CL, Ahlem CN, Murphy MF. NM101 Phase III study of NE3107 in Alzheimer\u2019s disease: rationale, design and therapeutic modulation of neuroinflammation and insulin resistance. Neurodegener Dis Manag. 2021;11:289\u201398.","journal-title":"Neurodegener Dis Manag"},{"key":"867_CR43","unstructured":"Anti-inflammatory Intervention with dapansutrile (OLT1177) for PD modification (DAPA-PD) (https:\/\/www.isrctn.com\/ISRCTN16806940)."},{"key":"867_CR44","unstructured":"Patricia In\u00e1cio P. 1st patient dosed in Phase 2 trial of Parkinson\u2019s therapy VTX3232. SAN DIEGO, June 17, 2025 (https:\/\/ir.ventyxbio.com\/node\/9471\/pdf)."},{"key":"867_CR45","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12974-023-02830-w","volume":"20","author":"J Amo-Aparicio","year":"2023","unstructured":"Amo-Aparicio J, Daly J, Hojen JF, Dinarello CA. Pharmacologic inhibition of NLRP3 reduces the levels of alpha-synuclein and protects dopaminergic neurons in a model of Parkinson\u2019s disease. J Neuroinflammation. 2023;20:147.","journal-title":"J Neuroinflammation"},{"key":"867_CR46","unstructured":"Marisa Wexler M: Zydus launches Phase 2 trial of anti-inflammatory ZYIL1. Ahmedabad, India, October 25, 2023."},{"key":"867_CR47","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1021\/acs.jmedchem.0c01773","volume":"65","author":"NM Tormahlen","year":"2022","unstructured":"Tormahlen NM, Martorelli M, Kuhn A, Maier F, Guezguez J, Burnet M, Albrecht W, Laufer SA, Koch P. Design and Synthesis of Highly Selective Brain Penetrant p38alpha Mitogen-Activated Protein Kinase Inhibitors. J Med Chem. 2022;65:1225\u201342.","journal-title":"J Med Chem"},{"key":"867_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/alz.042978","volume":"16","author":"K Baruch","year":"2020","unstructured":"Baruch K, Kertser A, Matalon O, Forsht O, Braiman S, Shochat E, David C, Yoles E. IBC-Ab002, an anti-PD-L1 monoclonal antibody tailored for treating Alzheimer\u2019s disease: Nonhuman\/Lead optimization studies. Alzheimer\u2019s & Dementia. 2020;16: e042978.","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"867_CR49","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1111\/cts.13317","volume":"15","author":"M Vissers","year":"2022","unstructured":"Vissers M, Heuberger J, Groeneveld GJ, Oude Nijhuis J, De Deyn PP, Hadi S, Harris J, Tsai RM, Cruz-Herranz A, Huang F, et al. Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blind phase I\/Ib studies in healthy subjects and patients. Clin Transl Sci. 2022;15:2010\u201323.","journal-title":"Clin Transl Sci"},{"key":"867_CR50","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13690","volume":"17","author":"A Hincelin-Mery","year":"2024","unstructured":"Hincelin-Mery A, Nicolas X, Cantalloube C, Pomponio R, Lewanczyk P, Benamor M, Ofengeim D, Krupka E, Hsiao-Nakamoto J, Eastenson A, Atassi N. Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants. Clin Transl Sci. 2024;17: e13690.","journal-title":"Clin Transl Sci"},{"key":"867_CR51","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.tins.2021.06.007","volume":"44","author":"A Guerrero","year":"2021","unstructured":"Guerrero A, De Strooper B, Arancibia-Carcamo IL. Cellular senescence at the crossroads of inflammation and Alzheimer\u2019s disease. Trends Neurosci. 2021;44:714\u201327.","journal-title":"Trends Neurosci"},{"key":"867_CR52","doi-asserted-by":"publisher","unstructured":"Garbarino VR, Palavicini JP, Melendez J, Barthelemy N, He Y, Kautz TF, Lopez-Cruzan M, Mathews JJ, Xu P, Zhan B, et al. Evaluation of Exploratory Fluid Biomarker Results from a Phase 1 Senolytic Trial in Mild Alzheimer\u2019s Disease. Preprint at https:\/\/doi.org\/10.21203\/rs.3.rs-3994894\/v1 (Res Sq. 2024)","DOI":"10.21203\/rs.3.rs-3994894\/v1"},{"key":"867_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.mad.2021.111589","volume":"200","author":"MM Gonzales","year":"2021","unstructured":"Gonzales MM, Krishnamurthy S, Garbarino V, Daeihagh AS, Gillispie GJ, Deep G, Craft S, Orr ME. A geroscience motivated approach to treat Alzheimer\u2019s disease: Senolytics move to clinical trials. Mech Ageing Dev. 2021;200: 111589.","journal-title":"Mech Ageing Dev"},{"key":"867_CR54","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13550-020-00683-5","volume":"10","author":"M Zammit","year":"2020","unstructured":"Zammit M, Tao Y, Olsen ME, Metzger J, Vermilyea SC, Bjornson K, Slesarev M, Block WF, Fuchs K, Phillips S, et al. [(18)F]FEPPA PET imaging for monitoring CD68-positive microglia\/macrophage neuroinflammation in nonhuman primates. EJNMMI Res. 2020;10:93.","journal-title":"EJNMMI Res"},{"key":"867_CR55","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1038\/s41380-020-0682-z","volume":"26","author":"NR Zurcher","year":"2021","unstructured":"Zurcher NR, Loggia ML, Mullett JE, Tseng C, Bhanot A, Richey L, Hightower BG, Wu C, Parmar AJ, Butterfield RI, et al. [(11)C]PBR28 MR-PET imaging reveals lower regional brain expression of translocator protein (TSPO) in young adult males with autism spectrum disorder. Mol Psychiatry. 2021;26:1659\u201369.","journal-title":"Mol Psychiatry"},{"key":"867_CR56","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13195-023-01169-x","volume":"15","author":"B Dubois","year":"2023","unstructured":"Dubois B, Lopez-Arrieta J, Lipschitz S, Doskas T, Spiru L, Moroz S, Venger O, Vermersch P, Moussy A, Mansfield CD, et al. Masitinib for mild-to-moderate Alzheimer\u2019s disease: results from a randomized, placebo-controlled, phase 3, clinical trial. Alzheimers Res Ther. 2023;15:39.","journal-title":"Alzheimers Res Ther"},{"key":"867_CR57","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1021\/acs.chemrestox.2c00057","volume":"35","author":"BD Latham","year":"2022","unstructured":"Latham BD, Oskin DS, Crouch RD, Vergne MJ, Jackson KD. Cytochromes P450 2C8 and 3A Catalyze the Metabolic Activation of the Tyrosine Kinase Inhibitor Masitinib. Chem Res Toxicol. 2022;35:1467\u201381.","journal-title":"Chem Res Toxicol"},{"key":"867_CR58","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3988\/jcn.2022.0379","volume":"19","author":"SM Lim","year":"2023","unstructured":"Lim SM, Nahm M, Kim SH. Proteostasis and Ribostasis Impairment as Common Cell Death Mechanisms in Neurodegenerative Diseases. J Clin Neurol. 2023;19:101\u201314.","journal-title":"J Clin Neurol"},{"key":"867_CR59","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1126\/science.aaf1064","volume":"351","author":"JG O\u2019Rourke","year":"2016","unstructured":"O\u2019Rourke JG, Bogdanik L, Yanez A, Lall D, Wolf AJ, Muhammad AK, Ho R, Carmona S, Vit JP, Zarrow J, et al. C9orf72 is required for proper macrophage and microglial function in mice. Science. 2016;351:1324\u20139.","journal-title":"Science"},{"issue":"1023\u20131031","key":"867_CR60","volume":"97","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Wu X, Li X, Jiang LL, Gui X, Liu Y, Sun Y, Zhu B, Pina-Crespo JC, Zhang M, et al. TREM2 Is a Receptor for beta-Amyloid that Mediates Microglial Function. Neuron. 2018;97(1023\u20131031): e1027.","journal-title":"Neuron"},{"issue":"979\u2013991","key":"867_CR61","volume":"48","author":"F Filipello","year":"2018","unstructured":"Filipello F, Morini R, Corradini I, Zerbi V, Canzi A, Michalski B, Erreni M, Markicevic M, Starvaggi-Cucuzza C, Otero K, et al. The Microglial Innate Immune Receptor TREM2 Is Required for Synapse Elimination and Normal Brain Connectivity. Immunity. 2018;48(979\u2013991): e978.","journal-title":"Immunity"},{"key":"867_CR62","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1001\/jamaneurol.2013.6237","volume":"71","author":"J Cady","year":"2014","unstructured":"Cady J, Koval ED, Benitez BA, Zaidman C, Jockel-Balsarotti J, Allred P, Baloh RH, Ravits J, Simpson E, Appel SH, et al. TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis. JAMA Neurol. 2014;71:449\u201353.","journal-title":"JAMA Neurol"},{"key":"867_CR63","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.msard.2019.07.007","volume":"35","author":"D Rikos","year":"2019","unstructured":"Rikos D, Siokas V, Aloizou AM, Tsouris Z, Aslanidou P, Koutsis G, Anagnostouli M, Bogdanos DP, Grigoriadis N, Hadjigeorgiou GM, Dardiotis E. TREM2 R47H (rs75932628) variant is unlikely to contribute to Multiple Sclerosis susceptibility and severity in a large Greek MS cohort. Mult Scler Relat Disord. 2019;35:116\u20138.","journal-title":"Mult Scler Relat Disord"},{"key":"867_CR64","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1080\/21678421.2018.1451894","volume":"19","author":"B Peplonska","year":"2018","unstructured":"Peplonska B, Berdynski M, Mandecka M, Barczak A, Kuzma-Kozakiewicz M, Barcikowska M, Zekanowski C. TREM2 variants in neurodegenerative disorders in the Polish population. Homozygosity and compound heterozygosity in FTD patients. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:407\u201312.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"867_CR65","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1080\/00207454.2020.1750388","volume":"131","author":"E Dardiotis","year":"2021","unstructured":"Dardiotis E, Rikos D, Siokas V, Aloizou AM, Tsouris Z, Sakalakis E, Brotis AG, Bogdanos DP, Hadjigeorgiou GM. Assessment of TREM2 rs75932628 variant\u2019s association with Parkinson\u2019s disease in a Greek population and Meta-analysis of current data. Int J Neurosci. 2021;131:544\u20138.","journal-title":"Int J Neurosci"},{"key":"867_CR66","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13024-017-0197-5","volume":"12","author":"TR Jay","year":"2017","unstructured":"Jay TR, von Saucken VE, Landreth GE. TREM2 in Neurodegenerative Diseases. Mol Neurodegener. 2017;12:56.","journal-title":"Mol Neurodegener"},{"key":"867_CR67","doi-asserted-by":"publisher","first-page":"5838","DOI":"10.1093\/hmg\/ddu277","volume":"23","author":"SC Jin","year":"2014","unstructured":"Jin SC, Benitez BA, Karch CM, Cooper B, Skorupa T, Carrell D, Norton JB, Hsu S, Harari O, Cai Y, et al. Coding variants in TREM2 increase risk for Alzheimer\u2019s disease. Hum Mol Genet. 2014;23:5838\u201346.","journal-title":"Hum Mol Genet"},{"key":"867_CR68","doi-asserted-by":"publisher","first-page":"992","DOI":"10.15252\/emmm.201606370","volume":"8","author":"X Xiang","year":"2016","unstructured":"Xiang X, Werner G, Bohrmann B, Liesz A, Mazaheri F, Capell A, Feederle R, Knuesel I, Kleinberger G, Haass C. TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance. EMBO Mol Med. 2016;8:992\u20131004.","journal-title":"EMBO Mol Med"},{"issue":"1283\u20131301","key":"867_CR69","volume":"109","author":"SH Lee","year":"2021","unstructured":"Lee SH, Meilandt WJ, Xie L, Gandham VD, Ngu H, Barck KH, Rezzonico MG, Imperio J, Lalehzadeh G, Huntley MA, et al. Trem2 restrains the enhancement of tau accumulation and neurodegeneration by beta-amyloid pathology. Neuron. 2021;109(1283\u20131301): e1286.","journal-title":"Neuron"},{"key":"867_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115218","volume":"165","author":"Y Li","year":"2023","unstructured":"Li Y, Xu H, Wang H, Yang K, Luan J, Wang S. TREM2: Potential therapeutic targeting of microglia for Alzheimer\u2019s disease. Biomed Pharmacother. 2023;165: 115218.","journal-title":"Biomed Pharmacother"},{"key":"867_CR71","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13024-017-0216-6","volume":"12","author":"SM Bemiller","year":"2017","unstructured":"Bemiller SM, McCray TJ, Allan K, Formica SV, Xu G, Wilson G, Kokiko-Cochran ON, Crish SD, Lasagna-Reeves CA, Ransohoff RM, et al. TREM2 deficiency exacerbates tau pathology through dysregulated kinase signaling in a mouse model of tauopathy. Mol Neurodegener. 2017;12:74.","journal-title":"Mol Neurodegener"},{"key":"867_CR72","doi-asserted-by":"publisher","first-page":"11524","DOI":"10.1073\/pnas.1710311114","volume":"114","author":"CEG Leyns","year":"2017","unstructured":"Leyns CEG, Ulrich JD, Finn MB, Stewart FR, Koscal LJ, Remolina Serrano J, Robinson GO, Anderson E, Colonna M, Holtzman DM. TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. Proc Natl Acad Sci U S A. 2017;114:11524\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"867_CR73","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.cell.2015.01.049","volume":"160","author":"Y Wang","year":"2015","unstructured":"Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer\u2019s disease model. Cell. 2015;160:1061\u201371.","journal-title":"Cell"},{"issue":"837\u2013854","key":"867_CR74","volume":"105","author":"AA Nugent","year":"2020","unstructured":"Nugent AA, Lin K, van Lengerich B, Lianoglou S, Przybyla L, Davis SS, Llapashtica C, Wang J, Kim DJ, Xia D, et al. TREM2 Regulates Microglial Cholesterol Metabolism upon Chronic Phagocytic Challenge. Neuron. 2020;105(837\u2013854): e839.","journal-title":"Neuron"},{"key":"867_CR75","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/s41593-024-01620-8","volume":"27","author":"N Rachmian","year":"2024","unstructured":"Rachmian N, Medina S, Cherqui U, Akiva H, Deitch D, Edilbi D, Croese T, Salame TM, Ramos JMP, Cahalon L, et al. Identification of senescent, TREM2-expressing microglia in aging and Alzheimer\u2019s disease model mouse brain. Nat Neurosci. 2024;27:1116\u201324.","journal-title":"Nat Neurosci"},{"key":"867_CR76","doi-asserted-by":"crossref","unstructured":"Wang S, Mustafa M, Yuede CM, Salazar SV, Kong P, Long H, Ward M, Siddiqui O, Paul R, Gilfillan S, et al. Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer\u2019s disease model. J Exp Med. 2020;217:e20200785.","DOI":"10.1084\/jem.20200785"},{"key":"867_CR77","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s13195-024-01599-1","volume":"16","author":"H Long","year":"2024","unstructured":"Long H, Simmons A, Mayorga A, Burgess B, Nguyen T, Budda B, Rychkova A, Rhinn H, Tassi I, Ward M, et al. Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer\u2019s disease. Alzheimers Res Ther. 2024;16:235.","journal-title":"Alzheimers Res Ther"},{"key":"867_CR78","doi-asserted-by":"publisher","first-page":"466","DOI":"10.15252\/emmm.201506123","volume":"8","author":"M Suarez-Calvet","year":"2016","unstructured":"Suarez-Calvet M, Kleinberger G, Araque Caballero MA, Brendel M, Rominger A, Alcolea D, Fortea J, Lleo A, Blesa R, Gispert JD, et al. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer\u2019s disease and associate with neuronal injury markers. EMBO Mol Med. 2016;8:466\u201376.","journal-title":"EMBO Mol Med"},{"key":"867_CR79","doi-asserted-by":"publisher","first-page":"369ra178","DOI":"10.1126\/scitranslmed.aag1767","volume":"8","author":"M Suarez-Calvet","year":"2016","unstructured":"Suarez-Calvet M, Araque Caballero MA, Kleinberger G, Bateman RJ, Fagan AM, Morris JC, Levin J, Danek A, Ewers M, Haass C, Dominantly Inherited Alzheimer N. Early changes in CSF sTREM2 in dominantly inherited Alzheimer\u2019s disease occur after amyloid deposition and neuronal injury. Sci Transl Med. 2016;8:369ra178.","journal-title":"Sci Transl Med"},{"key":"867_CR80","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00401-016-1533-5","volume":"131","author":"L Piccio","year":"2016","unstructured":"Piccio L, Deming Y, Del-Aguila JL, Ghezzi L, Holtzman DM, Fagan AM, Fenoglio C, Galimberti D, Borroni B, Cruchaga C. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol. 2016;131:925\u201333.","journal-title":"Acta Neuropathol"},{"key":"867_CR81","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13024-016-0071-x","volume":"11","author":"A Heslegrave","year":"2016","unstructured":"Heslegrave A, Heywood W, Paterson R, Magdalinou N, Svensson J, Johansson P, Ohrfelt A, Blennow K, Hardy J, Schott J, et al. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer\u2019s disease. Mol Neurodegener. 2016;11:3.","journal-title":"Mol Neurodegener"},{"key":"867_CR82","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12465","volume":"10","author":"J Cummings","year":"2024","unstructured":"Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. Not Available. Alzheimers Dement (N Y). 2024;10: e12465.","journal-title":"Alzheimers Dement (N Y)"},{"key":"867_CR83","unstructured":"Vigil neuroscience announces interim data from its ongoing phase 1 clinical trial evaluating VG-3927 in healthy volunteers supporting continued development in Alzheimer\u2019s disease. WATERTOWN, Mass., Jan. 23, 2025."},{"key":"867_CR84","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201911227","volume":"12","author":"K Schlepckow","year":"2020","unstructured":"Schlepckow K, Monroe KM, Kleinberger G, Cantuti-Castelvetri L, Parhizkar S, Xia D, Willem M, Werner G, Pettkus N, Brunner B, et al. Enhancing protective microglial activities with a dual function TREM2 antibody to the stalk region. EMBO Mol Med. 2020;12: e11227.","journal-title":"EMBO Mol Med"},{"key":"867_CR85","first-page":"416","volume":"26","author":"B van Lengerich","year":"2023","unstructured":"van Lengerich B, Zhan L, Xia D, Chan D, Joy D, Park JI, Tatarakis D, Calvert M, Hummel S, Lianoglou S, et al. A TREM2-activating antibody with a blood-brain barrier transport vehicle enhances microglial metabolism in Alzheimer\u2019s disease models. Nat Neurosci. 2023;26:416\u201329.","journal-title":"Nat Neurosci"},{"key":"867_CR86","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00401-019-02000-4","volume":"138","author":"S Estus","year":"2019","unstructured":"Estus S, Shaw BC, Devanney N, Katsumata Y, Press EE, Fardo DW. Evaluation of CD33 as a genetic risk factor for Alzheimer\u2019s disease. Acta Neuropathol. 2019;138:187\u201399.","journal-title":"Acta Neuropathol"},{"key":"867_CR87","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.neuron.2013.04.014","volume":"78","author":"A Griciuc","year":"2013","unstructured":"Griciuc A, Serrano-Pozo A, Parrado AR, Lesinski AN, Asselin CN, Mullin K, Hooli B, Choi SH, Hyman BT, Tanzi RE. Alzheimer\u2019s disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron. 2013;78:631\u201343.","journal-title":"Neuron"},{"key":"867_CR88","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1093\/hmg\/ddaa179","volume":"29","author":"A Griciuc","year":"2020","unstructured":"Griciuc A, Federico AN, Natasan J, Forte AM, McGinty D, Nguyen H, Volak A, LeRoy S, Gandhi S, Lerner EP, et al. Gene therapy for Alzheimer\u2019s disease targeting CD33 reduces amyloid beta accumulation and neuroinflammation. Hum Mol Genet. 2020;29:2920\u201335.","journal-title":"Hum Mol Genet"},{"key":"867_CR89","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12179","volume":"7","author":"J Cummings","year":"2021","unstructured":"Cummings J, Lee G, Zhong K, Fonseca J, Taghva K. Alzheimer\u2019s disease drug development pipeline: 2021. Alzheimers Dement (N Y). 2021;7: e12179.","journal-title":"Alzheimers Dement (N Y)"},{"key":"867_CR90","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.tips.2021.11.015","volume":"43","author":"H Rhinn","year":"2022","unstructured":"Rhinn H, Tatton N, McCaughey S, Kurnellas M, Rosenthal A. Progranulin as a therapeutic target in neurodegenerative diseases. Trends Pharmacol Sci. 2022;43:641\u201352.","journal-title":"Trends Pharmacol Sci"},{"key":"867_CR91","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12974-024-03039-1","volume":"21","author":"W Sung","year":"2024","unstructured":"Sung W, Noh MY, Nahm M, Kim YS, Ki CS, Kim YE, Kim HJ, Kim SH. Progranulin haploinsufficiency mediates cytoplasmic TDP-43 aggregation with lysosomal abnormalities in human microglia. J Neuroinflammation. 2024;21:47.","journal-title":"J Neuroinflammation"},{"key":"867_CR92","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.cell.2016.04.001","volume":"165","author":"H Lui","year":"2016","unstructured":"Lui H, Zhang J, Makinson SR, Cahill MK, Kelley KW, Huang HY, Shang Y, Oldham MC, Martens LH, Gao F, et al. Progranulin Deficiency Promotes Circuit-Specific Synaptic Pruning by Microglia via Complement Activation. Cell. 2016;165:921\u201335.","journal-title":"Cell"},{"key":"867_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109581","volume":"36","author":"Y Wu","year":"2021","unstructured":"Wu Y, Shao W, Todd TW, Tong J, Yue M, Koga S, Castanedes-Casey M, Librero AL, Lee CW, Mackenzie IR, et al. Microglial lysosome dysfunction contributes to white matter pathology and TDP-43 proteinopathy in GRN-associated FTD. Cell Rep. 2021;36: 109581.","journal-title":"Cell Rep"},{"key":"867_CR94","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/j.ajpath.2010.12.051","volume":"178","author":"JD Sokolowski","year":"2011","unstructured":"Sokolowski JD, Mandell JW. Phagocytic clearance in neurodegeneration. Am J Pathol. 2011;178:1416\u201328.","journal-title":"Am J Pathol"},{"key":"867_CR95","doi-asserted-by":"publisher","first-page":"R533","DOI":"10.1016\/j.cub.2011.05.053","volume":"21","author":"RJ Botelho","year":"2011","unstructured":"Botelho RJ, Grinstein S. Phagocytosis. Curr Biol. 2011;21:R533-538.","journal-title":"Curr Biol"},{"key":"867_CR96","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41586-019-1088-4","volume":"568","author":"JV Pluvinage","year":"2019","unstructured":"Pluvinage JV, Haney MS, Smith BAH, Sun J, Iram T, Bonanno L, Li L, Lee DP, Morgens DW, Yang AC, et al. CD22 blockade restores homeostatic microglial phagocytosis in ageing brains. Nature. 2019;568:187\u201392.","journal-title":"Nature"},{"key":"867_CR97","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.immuni.2014.02.009","volume":"40","author":"CD Buckley","year":"2014","unstructured":"Buckley CD, Gilroy DW, Serhan CN. Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity. 2014;40:315\u201327.","journal-title":"Immunity"},{"key":"867_CR98","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1084\/jem.20020760","volume":"196","author":"CN Serhan","year":"2002","unstructured":"Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, Moussignac RL. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med. 2002;196:1025\u201337.","journal-title":"J Exp Med"},{"key":"867_CR99","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1007\/s12035-015-9544-0","volume":"53","author":"M Zhu","year":"2016","unstructured":"Zhu M, Wang X, Hjorth E, Colas RA, Schroeder L, Granholm AC, Serhan CN, Schultzberg M. Pro-Resolving Lipid Mediators Improve Neuronal Survival and Increase Abeta42 Phagocytosis. Mol Neurobiol. 2016;53:2733\u201349.","journal-title":"Mol Neurobiol"},{"key":"867_CR100","doi-asserted-by":"publisher","first-page":"175628641879110","DOI":"10.1177\/1756286418791107","volume":"11","author":"M Zhu","year":"2018","unstructured":"Zhu M, Wang X, Sun L, Schultzberg M, Hjorth E. Can inflammation be resolved in Alzheimer\u2019s disease? Ther Adv Neurol Disord. 2018;11:1756286418791107.","journal-title":"Ther Adv Neurol Disord"},{"issue":"40\u201350","key":"867_CR101","first-page":"e41","volume":"11","author":"X Wang","year":"2015","unstructured":"Wang X, Zhu M, Hjorth E, Cortes-Toro V, Eyjolfsdottir H, Graff C, Nennesmo I, Palmblad J, Eriksdotter M, Sambamurti K, et al. Resolution of inflammation is altered in Alzheimer\u2019s disease. Alzheimers Dement. 2015;11(40\u201350):e41-42.","journal-title":"Alzheimers Dement"},{"key":"867_CR102","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1038\/s41467-018-03674-2","volume":"9","author":"JY Lee","year":"2018","unstructured":"Lee JY, Han SH, Park MH, Baek B, Song IS, Choi MK, Takuwa Y, Ryu H, Kim SH, He X, et al. Neuronal SphK1 acetylates COX2 and contributes to pathogenesis in a model of Alzheimer\u2019s Disease. Nat Commun. 2018;9:1479.","journal-title":"Nat Commun"},{"key":"867_CR103","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1038\/s41467-020-16080-4","volume":"11","author":"JY Lee","year":"2020","unstructured":"Lee JY, Han SH, Park MH, Song IS, Choi MK, Yu E, Park CM, Kim HJ, Kim SH, Schuchman EH, et al. N-AS-triggered SPMs are direct regulators of microglia in a model of Alzheimer\u2019s disease. Nat Commun. 2020;11:2358.","journal-title":"Nat Commun"},{"key":"867_CR104","doi-asserted-by":"publisher","first-page":"4761","DOI":"10.1007\/s12035-023-03339-2","volume":"60","author":"MY Noh","year":"2023","unstructured":"Noh MY, Kwon MS, Oh KW, Nahm M, Park J, Kim YE, Ki CS, Jin HK, Bae JS, Kim SH. Role of NCKAP1 in the Defective Phagocytic Function of Microglia-Like Cells Derived from Rapidly Progressing Sporadic ALS. Mol Neurobiol. 2023;60:4761\u201377.","journal-title":"Mol Neurobiol"},{"key":"867_CR105","doi-asserted-by":"crossref","unstructured":"Noh MY, Kwon MS, Oh KW, Nahm M, Park J, Jin HK, Bae JS, Son B, Kim SH: miRNA-214 to predict progression and survival in ALS. J Neurol Neurosurg Psychiatry 2025 Jun 12;96(7):716-720.","DOI":"10.1136\/jnnp-2024-335177"},{"key":"867_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116123","volume":"171","author":"H Dong","year":"2024","unstructured":"Dong H, Yan J, Huang P, Wang X, Zhang R, Zhang C, Wang W, Qian W, Zhou J, Zhao Y, et al. miR-214-3p promotes the pathogenesis of Parkinson\u2019s disease by inhibiting autophagy. Biomed Pharmacother. 2024;171: 116123.","journal-title":"Biomed Pharmacother"},{"key":"867_CR107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuron.2022.11.014","volume":"111","author":"H Davis","year":"2023","unstructured":"Davis H, Attwell D. Plaque attack: Microglia have hard feelings toward amyloid-beta. Neuron. 2023;111:1\u20132.","journal-title":"Neuron"},{"key":"867_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2023.102026","volume":"90","author":"B Zong","year":"2023","unstructured":"Zong B, Yu F, Zhang X, Pang Y, Zhao W, Sun P, Li L. Mechanosensitive Piezo1 channel in physiology and pathophysiology of the central nervous system. Ageing Res Rev. 2023;90: 102026.","journal-title":"Ageing Res Rev"},{"issue":"15\u201329","key":"867_CR109","volume":"111","author":"J Hu","year":"2023","unstructured":"Hu J, Chen Q, Zhu H, Hou L, Liu W, Yang Q, Shen H, Chai G, Zhang B, Chen S, et al. Microglial Piezo1 senses Abeta fibril stiffness to restrict Alzheimer\u2019s disease. Neuron. 2023;111(15\u201329): e18.","journal-title":"Neuron"},{"key":"867_CR110","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40478-017-0472-2","volume":"5","author":"JE Schweig","year":"2017","unstructured":"Schweig JE, Yao H, Beaulieu-Abdelahad D, Ait-Ghezala G, Mouzon B, Crawford F, Mullan M, Paris D. Alzheimer\u2019s disease pathological lesions activate the spleen tyrosine kinase. Acta Neuropathol Commun. 2017;5:69.","journal-title":"Acta Neuropathol Commun"},{"key":"867_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2024.106656","volume":"201","author":"T Yamaguchi","year":"2024","unstructured":"Yamaguchi T, Hamano T, Sada K, Asano R, Kanaan NM, Sasaki H, Yen SH, Kitazaki Y, Endo Y, Enomoto S, et al. Syk inhibitors reduce tau protein phosphorylation and oligomerization. Neurobiol Dis. 2024;201: 106656.","journal-title":"Neurobiol Dis"},{"issue":"4153\u20134169","key":"867_CR112","volume":"185","author":"S Wang","year":"2022","unstructured":"Wang S, Sudan R, Peng V, Zhou Y, Du S, Yuede CM, Lei T, Hou J, Cai Z, Cella M, et al. TREM2 drives microglia response to amyloid-beta via SYK-dependent and -independent pathways. Cell. 2022;185(4153\u20134169): e4119.","journal-title":"Cell"},{"issue":"4135\u20134152","key":"867_CR113","volume":"185","author":"H Ennerfelt","year":"2022","unstructured":"Ennerfelt H, Frost EL, Shapiro DA, Holliday C, Zengeler KE, Voithofer G, Bolte AC, Lammert CR, Kulas JA, Ulland TK, Lukens JR. SYK coordinates neuroprotective microglial responses in neurodegenerative disease. Cell. 2022;185(4135\u20134152): e4122.","journal-title":"Cell"},{"key":"867_CR114","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41590-021-00913-5","volume":"22","author":"Y Huang","year":"2021","unstructured":"Huang Y, Happonen KE, Burrola PG, O\u2019Connor C, Hah N, Huang L, Nimmerjahn A, Lemke G. Microglia use TAM receptors to detect and engulf amyloid beta plaques. Nat Immunol. 2021;22:586\u201394.","journal-title":"Nat Immunol"},{"key":"867_CR115","doi-asserted-by":"crossref","unstructured":"Lew ED, Oh J, Burrola PG, Lax I, Zagorska A, Traves PG, Schlessinger J, Lemke G. Differential TAM receptor-ligand-phospholipid interactions delimit differential TAM bioactivities. Elife. 2014;3:e03385","DOI":"10.7554\/eLife.03385"},{"key":"867_CR116","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1038\/s41591-022-01926-9","volume":"28","author":"H Jung","year":"2022","unstructured":"Jung H, Lee SY, Lim S, Choi HR, Choi Y, Kim M, Kim S, Lee Y, Han KH, Chung WS, Kim CH. Anti-inflammatory clearance of amyloid-beta by a chimeric Gas6 fusion protein. Nat Med. 2022;28:1802\u201312.","journal-title":"Nat Med"},{"key":"867_CR117","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.tips.2017.10.008","volume":"39","author":"IV Kurochkin","year":"2018","unstructured":"Kurochkin IV, Guarnera E, Berezovsky IN. Insulin-Degrading Enzyme in the Fight against Alzheimer\u2019s Disease. Trends Pharmacol Sci. 2018;39:49\u201358.","journal-title":"Trends Pharmacol Sci"},{"key":"867_CR118","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s12974-023-02914-7","volume":"20","author":"M Corraliza-Gomez","year":"2023","unstructured":"Corraliza-Gomez M, Bermejo T, Lilue J, Rodriguez-Iglesias N, Valero J, Cozar-Castellano I, Arranz E, Sanchez D, Ganfornina MD. Insulin-degrading enzyme (IDE) as a modulator of microglial phenotypes in the context of Alzheimer\u2019s disease and brain aging. J Neuroinflammation. 2023;20:233.","journal-title":"J Neuroinflammation"},{"key":"867_CR119","doi-asserted-by":"publisher","first-page":"32730","DOI":"10.1074\/jbc.273.49.32730","volume":"273","author":"WQ Qiu","year":"1998","unstructured":"Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, Rosner MR, Safavi A, Hersh LB, Selkoe DJ. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem. 1998;273:32730\u20138.","journal-title":"J Biol Chem"},{"key":"867_CR120","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.neurobiolaging.2005.01.004","volume":"27","author":"WQ Qiu","year":"2006","unstructured":"Qiu WQ, Folstein MF. Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer\u2019s disease: review and hypothesis. Neurobiol Aging. 2006;27:190\u20138.","journal-title":"Neurobiol Aging"},{"key":"867_CR121","doi-asserted-by":"publisher","first-page":"8090","DOI":"10.1523\/JNEUROSCI.1089-23.2023","volume":"43","author":"JM Dundee","year":"2023","unstructured":"Dundee JM, Puigdellivol M, Butler R, Brown GC. P2Y(6) Receptor-Dependent Microglial Phagocytosis of Synapses during Development Regulates Synapse Density and Memory. J Neurosci. 2023;43:8090\u2013103.","journal-title":"J Neurosci"},{"key":"867_CR122","doi-asserted-by":"publisher","first-page":"eadj9052","DOI":"10.1126\/scitranslmed.adj9052","volume":"16","author":"J Hou","year":"2024","unstructured":"Hou J, Chen Y, Cai Z, Heo GS, Yuede CM, Wang Z, Lin K, Saadi F, Trsan T, Nguyen AT, et al. Antibody-mediated targeting of human microglial leukocyte Ig-like receptor B4 attenuates amyloid pathology in a mouse model. Sci Transl Med. 2024;16:eadj9052.","journal-title":"Sci Transl Med"},{"key":"867_CR123","doi-asserted-by":"publisher","first-page":"17321","DOI":"10.1523\/JNEUROSCI.1569-12.2012","volume":"32","author":"M Yamanaka","year":"2012","unstructured":"Yamanaka M, Ishikawa T, Griep A, Axt D, Kummer MP, Heneka MT. PPARgamma\/RXRalpha-induced and CD36-mediated microglial amyloid-beta phagocytosis results in cognitive improvement in amyloid precursor protein\/presenilin 1 mice. J Neurosci. 2012;32:17321\u201331.","journal-title":"J Neurosci"},{"key":"867_CR124","doi-asserted-by":"publisher","first-page":"E2705","DOI":"10.1073\/pnas.1604032113","volume":"113","author":"AK Fu","year":"2016","unstructured":"Fu AK, Hung KW, Yuen MY, Zhou X, Mak DS, Chan IC, Cheung TH, Zhang B, Fu WY, Liew FY, Ip NY. IL-33 ameliorates Alzheimer\u2019s disease-like pathology and cognitive decline. Proc Natl Acad Sci U S A. 2016;113:E2705-2713.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"867_CR125","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1126\/science.1123511","volume":"312","author":"S Boillee","year":"2006","unstructured":"Boillee S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, Kollias G, Cleveland DW. Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006;312:1389\u201392.","journal-title":"Science"},{"key":"867_CR126","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1083\/jcb.200908164","volume":"187","author":"H Ilieva","year":"2009","unstructured":"Ilieva H, Polymenidou M, Cleveland DW. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol. 2009;187:761\u201372.","journal-title":"J Cell Biol"},{"key":"867_CR127","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.expneurol.2012.06.011","volume":"237","author":"B Liao","year":"2012","unstructured":"Liao B, Zhao W, Beers DR, Henkel JS, Appel SH. Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS. Exp Neurol. 2012;237:147\u201352.","journal-title":"Exp Neurol"},{"key":"867_CR128","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1093\/brain\/awr074","volume":"134","author":"DR Beers","year":"2011","unstructured":"Beers DR, Henkel JS, Zhao W, Wang J, Huang A, Wen S, Liao B, Appel SH. Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain. 2011;134:1293\u2013314.","journal-title":"Brain"},{"key":"867_CR129","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1002\/sctm.16-0363","volume":"6","author":"C Lo Sicco","year":"2017","unstructured":"Lo Sicco C, Reverberi D, Balbi C, Ulivi V, Principi E, Pascucci L, Becherini P, Bosco MC, Varesio L, Franzin C, et al. Mesenchymal Stem Cell-Derived Extracellular Vesicles as Mediators of Anti-Inflammatory Effects: Endorsement of Macrophage Polarization. Stem Cells Transl Med. 2017;6:1018\u201328.","journal-title":"Stem Cells Transl Med"},{"key":"867_CR130","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.tips.2020.06.009","volume":"41","author":"N Song","year":"2020","unstructured":"Song N, Scholtemeijer M, Shah K. Mesenchymal Stem Cell Immunomodulation: Mechanisms and Therapeutic Potential. Trends Pharmacol Sci. 2020;41:653\u201364.","journal-title":"Trends Pharmacol Sci"},{"key":"867_CR131","first-page":"1657","volume":"18","author":"YY Liu","year":"2023","unstructured":"Liu YY, Li Y, Wang L, Zhao Y, Yuan R, Yang MM, Chen Y, Zhang H, Zhou FH, Qian ZR, Kang HJ. Mesenchymal stem cell-derived exosomes regulate microglia phenotypes: a promising treatment for acute central nervous system injury. Neural Regen Res. 2023;18:1657\u201365.","journal-title":"Neural Regen Res"},{"key":"867_CR132","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.5966\/sctm.2015-0217","volume":"5","author":"MY Noh","year":"2016","unstructured":"Noh MY, Lim SM, Oh KW, Cho KA, Park J, Kim KS, Lee SJ, Kwon MS, Kim SH. Mesenchymal Stem Cells Modulate the Functional Properties of Microglia via TGF-beta Secretion. Stem Cells Transl Med. 2016;5:1538\u201349.","journal-title":"Stem Cells Transl Med"},{"key":"867_CR133","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/ana.25302","volume":"84","author":"KW Oh","year":"2018","unstructured":"Oh KW, Noh MY, Kwon MS, Kim HY, Oh SI, Park J, Kim HJ, Ki CS, Kim SH. Repeated Intrathecal Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis. Ann Neurol. 2018;84:361\u201373.","journal-title":"Ann Neurol"},{"key":"867_CR134","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/stcltm\/szad095","volume":"13","author":"SH Kim","year":"2024","unstructured":"Kim SH, Oh KW, Noh MY, Kwon MS. Optimal Therapeutic Strategy of Bone Marrow-Originated Autologous Mesenchymal Stromal\/Stem Cells for ALS. Stem Cells Transl Med. 2024;13:309\u201316.","journal-title":"Stem Cells Transl Med"},{"key":"867_CR135","doi-asserted-by":"publisher","first-page":"6156","DOI":"10.1007\/s12035-019-1500-y","volume":"56","author":"S Swarbrick","year":"2019","unstructured":"Swarbrick S, Wragg N, Ghosh S, Stolzing A. Systematic Review of miRNA as Biomarkers in Alzheimer\u2019s Disease. Mol Neurobiol. 2019;56:6156\u201367.","journal-title":"Mol Neurobiol"},{"key":"867_CR136","doi-asserted-by":"publisher","first-page":"1391537","DOI":"10.3389\/fncel.2024.1391537","volume":"18","author":"SP Jadhav","year":"2024","unstructured":"Jadhav SP. MicroRNAs in microglia: deciphering their role in neurodegenerative diseases. Front Cell Neurosci. 2024;18:1391537.","journal-title":"Front Cell Neurosci"},{"key":"867_CR137","doi-asserted-by":"publisher","first-page":"12678","DOI":"10.1080\/21655979.2021.2008638","volume":"12","author":"W Wan","year":"2021","unstructured":"Wan W, Liu G, Li X, Liu Y, Wang Y, Pan H, Hu J. MiR-191-5p alleviates microglial cell injury by targeting Map3k12 (mitogen-activated protein kinase kinase kinase 12) to inhibit the MAPK (mitogen-activated protein kinase) signaling pathway in Alzheimer\u2019s disease. Bioengineered. 2021;12:12678\u201390.","journal-title":"Bioengineered"},{"key":"867_CR138","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1038\/s41593-023-01355-y","volume":"26","author":"Z Yin","year":"2023","unstructured":"Yin Z, Herron S, Silveira S, Kleemann K, Gauthier C, Mallah D, Cheng Y, Margeta MA, Pitts KM, Barry JL, et al. Identification of a protective microglial state mediated by miR-155 and interferon-gamma signaling in a mouse model of Alzheimer\u2019s disease. Nat Neurosci. 2023;26:1196\u2013207.","journal-title":"Nat Neurosci"},{"key":"867_CR139","doi-asserted-by":"publisher","first-page":"4103","DOI":"10.7150\/thno.53418","volume":"11","author":"C Liang","year":"2021","unstructured":"Liang C, Zou T, Zhang M, Fan W, Zhang T, Jiang Y, Cai Y, Chen F, Chen X, Sun Y, et al. MicroRNA-146a switches microglial phenotypes to resist the pathological processes and cognitive degradation of Alzheimer\u2019s disease. Theranostics. 2021;11:4103\u201321.","journal-title":"Theranostics"},{"key":"867_CR140","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/cdd.2015.153","volume":"23","author":"C Parisi","year":"2016","unstructured":"Parisi C, Napoli G, Amadio S, Spalloni A, Apolloni S, Longone P, Volonte C. MicroRNA-125b regulates microglia activation and motor neuron death in ALS. Cell Death Differ. 2016;23:531\u201341.","journal-title":"Cell Death Differ"},{"key":"867_CR141","doi-asserted-by":"crossref","unstructured":"Zingale VD, Gugliandolo A, Mazzon E. MiR-155: An Important Regulator of Neuroinflammation. Int J Mol Sci. 2021;23:90.","DOI":"10.3390\/ijms23010090"},{"key":"867_CR142","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/ana.24304","volume":"77","author":"O Butovsky","year":"2015","unstructured":"Butovsky O, Jedrychowski MP, Cialic R, Krasemann S, Murugaiyan G, Fanek Z, Greco DJ, Wu PM, Doykan CE, Kiner O, et al. Targeting miR-155 restores abnormal microglia and attenuates disease in SOD1 mice. Ann Neurol. 2015;77:75\u201399.","journal-title":"Ann Neurol"},{"key":"867_CR143","doi-asserted-by":"publisher","first-page":"8648","DOI":"10.1096\/fj.201900363R","volume":"33","author":"L Yao","year":"2019","unstructured":"Yao L, Zhu Z, Wu J, Zhang Y, Zhang H, Sun X, Qian C, Wang B, Xie L, Zhang S, Lu G. MicroRNA-124 regulates the expression of p62\/p38 and promotes autophagy in the inflammatory pathogenesis of Parkinson\u2019s disease. FASEB J. 2019;33:8648\u201365.","journal-title":"FASEB J"},{"key":"867_CR144","doi-asserted-by":"crossref","unstructured":"Gong X, Huang M, Chen L: Mechanism of miR-132\u20133p Promoting Neuroinflammation and Dopaminergic Neurodegeneration in Parkinson\u2019s Disease. eNeuro 2022;9.","DOI":"10.1523\/ENEURO.0393-21.2021"},{"key":"867_CR145","doi-asserted-by":"publisher","first-page":"eabl7634","DOI":"10.1126\/scitranslmed.abl7634","volume":"14","author":"M Moutinho","year":"2022","unstructured":"Moutinho M, Puntambekar SS, Tsai AP, Coronel I, Lin PB, Casali BT, Martinez P, Oblak AL, Lasagna-Reeves CA, Lamb BT, Landreth GE. The niacin receptor HCAR2 modulates microglial response and limits disease progression in a mouse model of Alzheimer\u2019s disease. Sci Transl Med. 2022;14:eabl7634.","journal-title":"Sci Transl Med"},{"key":"867_CR146","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41588-019-0358-2","volume":"51","author":"BW Kunkle","year":"2019","unstructured":"Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, Boland A, Vronskaya M, van der Lee SJ, Amlie-Wolf A, et al. Genetic meta-analysis of diagnosed Alzheimer\u2019s disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. Nat Genet. 2019;51:414\u201330.","journal-title":"Nat Genet"},{"key":"867_CR147","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.8346443","volume":"261","author":"EH Corder","year":"1993","unstructured":"Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late onset families. Science. 1993;261:921\u20133.","journal-title":"Science"},{"key":"867_CR148","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13024-022-00574-4","volume":"17","author":"AC Raulin","year":"2022","unstructured":"Raulin AC, Doss SV, Trottier ZA, Ikezu TC, Bu G, Liu CC. ApoE in Alzheimer\u2019s disease: pathophysiology and therapeutic strategies. Mol Neurodegener. 2022;17:72.","journal-title":"Mol Neurodegener"},{"key":"867_CR149","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41586-019-1195-2","volume":"570","author":"H Mathys","year":"2019","unstructured":"Mathys H, Davila-Velderrain J, Peng Z, Gao F, Mohammadi S, Young JZ, Menon M, He L, Abdurrob F, Jiang X, et al. Single-cell transcriptomic analysis of Alzheimer\u2019s disease. Nature. 2019;570:332\u20137.","journal-title":"Nature"},{"key":"867_CR150","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/1097-0029(20000815)50:4<316::AID-JEMT11>3.0.CO;2-E","volume":"50","author":"GM Cole","year":"2000","unstructured":"Cole GM, Ard MD. Influence of lipoproteins on microglial degradation of Alzheimer\u2019s amyloid beta-protein. Microsc Res Tech. 2000;50:316\u201324.","journal-title":"Microsc Res Tech"},{"key":"867_CR151","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.neuron.2008.04.010","volume":"58","author":"Q Jiang","year":"2008","unstructured":"Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, et al. ApoE promotes the proteolytic degradation of Abeta. Neuron. 2008;58:681\u201393.","journal-title":"Neuron"},{"key":"867_CR152","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1038\/s41590-023-01627-6","volume":"24","author":"Z Yin","year":"2023","unstructured":"Yin Z, Rosenzweig N, Kleemann KL, Zhang X, Brandao W, Margeta MA, Schroeder C, Sivanathan KN, Silveira S, Gauthier C, et al. APOE4 impairs the microglial response in Alzheimer\u2019s disease by inducing TGFbeta-mediated checkpoints. Nat Immunol. 2023;24:1839\u201353.","journal-title":"Nat Immunol"},{"key":"867_CR153","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41586-024-07185-7","volume":"628","author":"MS Haney","year":"2024","unstructured":"Haney MS, Palovics R, Munson CN, Long C, Johansson PK, Yip O, Dong W, Rawat E, West E, Schlachetzki JCM, et al. APOE4\/4 is linked to damaging lipid droplets in Alzheimer\u2019s disease microglia. Nature. 2024;628:154\u201361.","journal-title":"Nature"},{"key":"867_CR154","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13024-023-00693-6","volume":"18","author":"G Eskandari-Sedighi","year":"2023","unstructured":"Eskandari-Sedighi G, Blurton-Jones M. Microglial APOE4: more is less and less is more. Mol Neurodegener. 2023;18:99.","journal-title":"Mol Neurodegener"},{"issue":"1197\u20131212","key":"867_CR155","volume":"29","author":"MB Victor","year":"2022","unstructured":"Victor MB, Leary N, Luna X, Meharena HS, Scannail AN, Bozzelli PL, Samaan G, Murdock MH, von Maydell D, Effenberger AH, et al. Lipid accumulation induced by APOE4 impairs microglial surveillance of neuronal-network activity. Cell Stem Cell. 2022;29(1197\u20131212): e1198.","journal-title":"Cell Stem Cell"},{"key":"867_CR156","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.neuron.2016.06.015","volume":"91","author":"FL Yeh","year":"2016","unstructured":"Yeh FL, Wang Y, Tom I, Gonzalez LC, Sheng M. TREM2 Binds to Apolipoproteins, Including APOE and CLU\/APOJ, and Thereby Facilitates Uptake of Amyloid-Beta by Microglia. Neuron. 2016;91:328\u201340.","journal-title":"Neuron"},{"key":"867_CR157","doi-asserted-by":"publisher","first-page":"eabe3947","DOI":"10.1126\/scitranslmed.abe3947","volume":"13","author":"FA Sayed","year":"2021","unstructured":"Sayed FA, Kodama L, Fan L, Carling GK, Udeochu JC, Le D, Li Q, Zhou L, Wong MY, Horowitz R, et al. AD-linked R47H-TREM2 mutation induces disease-enhancing microglial states via AKT hyperactivation. Sci Transl Med. 2021;13:eabe3947.","journal-title":"Sci Transl Med"},{"key":"867_CR158","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1096\/fj.201902447R","volume":"34","author":"TM Piers","year":"2020","unstructured":"Piers TM, Cosker K, Mallach A, Johnson GT, Guerreiro R, Hardy J, Pocock JM. A locked immunometabolic switch underlies TREM2 R47H loss of function in human iPSC-derived microglia. FASEB J. 2020;34:2436\u201350.","journal-title":"FASEB J"},{"issue":"493\u2013507","key":"867_CR159","volume":"30","author":"SH Baik","year":"2019","unstructured":"Baik SH, Kang S, Lee W, Choi H, Chung S, Kim JI, Mook-Jung I. A Breakdown in Metabolic Reprogramming Causes Microglia Dysfunction in Alzheimer\u2019s Disease. Cell Metab. 2019;30(493\u2013507): e496.","journal-title":"Cell Metab"},{"key":"867_CR160","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.cmet.2020.08.002","volume":"32","author":"AF McGettrick","year":"2020","unstructured":"McGettrick AF, O\u2019Neill LAJ. The Role of HIF in Immunity and Inflammation. Cell Metab. 2020;32:524\u201336.","journal-title":"Cell Metab"},{"key":"867_CR161","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1080\/25785826.2020.1756609","volume":"43","author":"Y Iwasaki","year":"2020","unstructured":"Iwasaki Y, Takeshima Y, Fujio K. Basic mechanism of immune system activation by mitochondria. Immunol Med. 2020;43:142\u20137.","journal-title":"Immunol Med"},{"key":"867_CR162","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.920029","volume":"13","author":"Y Xu","year":"2022","unstructured":"Xu Y, Chen Y, Zhang X, Ma J, Liu Y, Cui L, Wang F. Glycolysis in Innate Immune Cells Contributes to Autoimmunity. Front Immunol. 2022;13: 920029.","journal-title":"Front Immunol"},{"key":"867_CR163","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2023.105614","volume":"171","author":"H Chen","year":"2023","unstructured":"Chen H, Guo Z, Sun Y, Dai X. The immunometabolic reprogramming of microglia in Alzheimer\u2019s disease. Neurochem Int. 2023;171: 105614.","journal-title":"Neurochem Int"},{"key":"867_CR164","doi-asserted-by":"crossref","unstructured":"Prakash P, Manchanda P, Paouri E, Bisht K, Sharma K, Rajpoot J, Wendt V, Hossain A, Wijewardhane PR, Randolph CE, et al. Amyloid beta Induces Lipid Droplet-Mediated Microglial Dysfunction in Alzheimer\u2019s Disease. Immunity. 2025;58:1536-52.","DOI":"10.1016\/j.immuni.2025.04.029"},{"key":"867_CR165","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1038\/s42255-022-00643-4","volume":"4","author":"L Leng","year":"2022","unstructured":"Leng L, Yuan Z, Pan R, Su X, Wang H, Xue J, Zhuang K, Gao J, Chen Z, Lin H, et al. Microglial hexokinase 2 deficiency increases ATP generation through lipid metabolism leading to beta-amyloid clearance. Nat Metab. 2022;4:1287\u2013305.","journal-title":"Nat Metab"},{"key":"867_CR166","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s00401-020-02129-7","volume":"139","author":"KS Rawji","year":"2020","unstructured":"Rawji KS, Young AMH, Ghosh T, Michaels NJ, Mirzaei R, Kappen J, Kolehmainen KL, Alaeiilkhchi N, Lozinski B, Mishra MK, et al. Niacin-mediated rejuvenation of macrophage\/microglia enhances remyelination of the aging central nervous system. Acta Neuropathol. 2020;139:893\u2013909.","journal-title":"Acta Neuropathol"},{"issue":"634\u2013648","key":"867_CR167","volume":"34","author":"RY Pan","year":"2022","unstructured":"Pan RY, He L, Zhang J, Liu X, Liao Y, Gao J, Liao Y, Yan Y, Li Q, Zhou X, et al. Positive feedback regulation of microglial glucose metabolism by histone H4 lysine 12 lactylation in Alzheimer\u2019s disease. Cell Metab. 2022;34(634\u2013648): e636.","journal-title":"Cell Metab"},{"key":"867_CR168","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1212\/WNL.58.8.1277","volume":"58","author":"G Almer","year":"2002","unstructured":"Almer G, Teismann P, Stevic Z, Halaschek-Wiener J, Deecke L, Kostic V, Przedborski S. Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patients. Neurology. 2002;58:1277\u20139.","journal-title":"Neurology"},{"key":"867_CR169","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1034\/j.1600-0404.2003.00102.x","volume":"108","author":"J Ilzecka","year":"2003","unstructured":"Ilzecka J. Prostaglandin E2 is increased in amyotrophic lateral sclerosis patients. Acta Neurol Scand. 2003;108:125\u20139.","journal-title":"Acta Neurol Scand"},{"key":"867_CR170","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1212\/WNL.55.2.323","volume":"55","author":"L Ho","year":"2000","unstructured":"Ho L, Luterman JD, Aisen PS, Pasinetti GM, Montine TJ, Morrow JD. Elevated CSF prostaglandin E2 levels in patients with probable AD. Neurology. 2000;55:323.","journal-title":"Neurology"},{"key":"867_CR171","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s41586-020-03160-0","volume":"590","author":"PS Minhas","year":"2021","unstructured":"Minhas PS, Latif-Hernandez A, McReynolds MR, Durairaj AS, Wang Q, Rubin A, Joshi AU, He JQ, Gauba E, Liu L, et al. Restoring metabolism of myeloid cells reverses cognitive decline in ageing. Nature. 2021;590:122\u20138.","journal-title":"Nature"},{"key":"867_CR172","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13024-024-00735-7","volume":"19","author":"Y Hu","year":"2024","unstructured":"Hu Y, Hruscha A, Pan C, Schifferer M, Schmidt MK, Nuscher B, Giera M, Kostidis S, Burhan O, van Bebber F, et al. Mis-localization of endogenous TDP-43 leads to ALS-like early-stage metabolic dysfunction and progressive motor deficits. Mol Neurodegener. 2024;19:50.","journal-title":"Mol Neurodegener"},{"issue":"297\u2013308","key":"867_CR173","volume":"95","author":"RC Paolicelli","year":"2017","unstructured":"Paolicelli RC, Jawaid A, Henstridge CM, Valeri A, Merlini M, Robinson JL, Lee EB, Rose J, Appel S, Lee VM, et al. TDP-43 Depletion in Microglia Promotes Amyloid Clearance but Also Induces Synapse Loss. Neuron. 2017;95(297\u2013308): e296.","journal-title":"Neuron"},{"key":"867_CR174","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1007\/s10072-023-07259-w","volume":"45","author":"AA Hamad","year":"2024","unstructured":"Hamad AA, Amer BE, Hawas Y, Mabrouk MA, Meshref M. Masitinib as a neuroprotective agent: a scoping review of preclinical and clinical evidence. Neurol Sci. 2024;45:1861\u201373.","journal-title":"Neurol Sci"},{"key":"867_CR175","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.3233\/JAD-200466","volume":"76","author":"T Li","year":"2020","unstructured":"Li T, Martin E, Abada YS, Boucher C, Ces A, Youssef I, Fenaux G, Forand Y, Legrand A, Nachiket N, et al. Effects of Chronic Masitinib Treatment in APPswe\/PSEN1dE9 Transgenic Mice Modeling Alzheimer\u2019s Disease. J Alzheimers Dis. 2020;76:1339\u201345.","journal-title":"J Alzheimers Dis"},{"key":"867_CR176","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1159\/000255051","volume":"28","author":"OV Forlenza","year":"2009","unstructured":"Forlenza OV, Diniz BS, Talib LL, Mendonca VA, Ojopi EB, Gattaz WF, Teixeira AL. Increased serum IL-1beta level in Alzheimer\u2019s disease and mild cognitive impairment. Dement Geriatr Cogn Disord. 2009;28:507\u201312.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"867_CR177","doi-asserted-by":"publisher","first-page":"1196413","DOI":"10.3389\/fphar.2023.1196413","volume":"14","author":"D Melchiorri","year":"2023","unstructured":"Melchiorri D, Merlo S, Micallef B, Borg JJ, Drafi F. Alzheimer\u2019s disease and neuroinflammation: will new drugs in clinical trials pave the way to a multi-target therapy? Front Pharmacol. 2023;14:1196413.","journal-title":"Front Pharmacol"},{"key":"867_CR178","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s13760-020-01477-1","volume":"121","author":"T Yazar","year":"2021","unstructured":"Yazar T, Olgun Yazar H, Cihan M. Evaluation of serum galectin-3 levels at Alzheimer patients by stages: a preliminary report. Acta Neurol Belg. 2021;121:949\u201354.","journal-title":"Acta Neurol Belg"},{"key":"867_CR179","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s00401-022-02469-6","volume":"144","author":"A Boza-Serrano","year":"2022","unstructured":"Boza-Serrano A, Vrillon A, Minta K, Paulus A, Camprubi-Ferrer L, Garcia M, Andreasson U, Antonell A, Wennstrom M, Gouras G, et al. Galectin-3 is elevated in CSF and is associated with Abeta deposits and tau aggregates in brain tissue in Alzheimer\u2019s disease. Acta Neuropathol. 2022;144:843\u201359.","journal-title":"Acta Neuropathol"},{"key":"867_CR180","doi-asserted-by":"publisher","first-page":"1345625","DOI":"10.3389\/fimmu.2024.1345625","volume":"15","author":"H Zheng","year":"2024","unstructured":"Zheng H, Liu Q, Zhou S, Luo H, Zhang W. Role and therapeutic targets of P2X7 receptors in neurodegenerative diseases. Front Immunol. 2024;15:1345625.","journal-title":"Front Immunol"},{"key":"867_CR181","unstructured":"Lobo A: First patient dosed in Parkinson\u2019s clinical trial of Ventus\u2019 VENT-02. In Book First patient dosed in Parkinson\u2019s clinical trial of Ventus\u2019 VENT-02 (Editor ed.^eds.). City; 2025."},{"key":"867_CR182","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","volume":"19","author":"KV Swanson","year":"2019","unstructured":"Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19:477\u201389.","journal-title":"Nat Rev Immunol"},{"key":"867_CR183","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2024.104810","volume":"397\u2013398","author":"X Chen","year":"2024","unstructured":"Chen X, Zhang P, Zhang Y, Wei M, Tian T, Zhu D, Guan Y, Wei W, Ma Y. The research progression of direct NLRP3 inhibitors to treat inflammatory disorders. Cell Immunol. 2024;397\u2013398: 104810.","journal-title":"Cell Immunol"},{"key":"867_CR184","doi-asserted-by":"publisher","first-page":"32145","DOI":"10.1073\/pnas.2009680117","volume":"117","author":"N Lonnemann","year":"2020","unstructured":"Lonnemann N, Hosseini S, Marchetti C, Skouras DB, Stefanoni D, D\u2019Alessandro A, Dinarello CA, Korte M. The NLRP3 inflammasome inhibitor OLT1177 rescues cognitive impairment in a mouse model of Alzheimer\u2019s disease. Proc Natl Acad Sci U S A. 2020;117:32145\u201354.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"867_CR185","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/s41419-022-05290-x","volume":"13","author":"J Flores","year":"2022","unstructured":"Flores J, Fillion ML, LeBlanc AC. Caspase-1 inhibition improves cognition without significantly altering amyloid and inflammation in aged Alzheimer disease mice. Cell Death Dis. 2022;13:864.","journal-title":"Cell Death Dis"},{"key":"867_CR186","unstructured":"Davide Basco P: Targeting the Inflammasome Pathway with an ANTI-ASC Immunotherapy in Alzheimer\u2019s Disease. AD\/PD 2024."},{"key":"867_CR187","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/nrm3683","volume":"14","author":"D Ofengeim","year":"2013","unstructured":"Ofengeim D, Yuan J. Regulation of RIP1 kinase signalling at the crossroads of inflammation and cell death. Nat Rev Mol Cell Biol. 2013;14:727\u201336.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"867_CR188","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1126\/science.aaf6803","volume":"353","author":"Y Ito","year":"2016","unstructured":"Ito Y, Ofengeim D, Najafov A, Das S, Saberi S, Li Y, Hitomi J, Zhu H, Chen H, Mayo L, et al. RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS. Science. 2016;353:603\u20138.","journal-title":"Science"},{"key":"867_CR189","doi-asserted-by":"publisher","first-page":"E8788","DOI":"10.1073\/pnas.1714175114","volume":"114","author":"D Ofengeim","year":"2017","unstructured":"Ofengeim D, Mazzitelli S, Ito Y, DeWitt JP, Mifflin L, Zou C, Das S, Adiconis X, Chen H, Zhu H, et al. RIPK1 mediates a disease-associated microglial response in Alzheimer\u2019s disease. Proc Natl Acad Sci U S A. 2017;114:E8788\u201397.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"867_CR190","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1016\/j.celrep.2018.01.089","volume":"22","author":"A Iannielli","year":"2018","unstructured":"Iannielli A, Bido S, Folladori L, Segnali A, Cancellieri C, Maresca A, Massimino L, Rubio A, Morabito G, Caporali L, et al. Pharmacological Inhibition of Necroptosis Protects from Dopaminergic Neuronal Cell Death in Parkinson\u2019s Disease Models. Cell Rep. 2018;22:2066\u201379.","journal-title":"Cell Rep"},{"key":"867_CR191","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/cpt.1615","volume":"107","author":"HW Grievink","year":"2020","unstructured":"Grievink HW, Heuberger J, Huang F, Chaudhary R, Birkhoff WAJ, Tonn GR, Mosesova S, Erickson R, Moerland M, Haddick PCG, et al. DNL104, a Centrally Penetrant RIPK1 Inhibitor, Inhibits RIP1 Kinase Phosphorylation in a Randomized Phase I Ascending Dose Study in Healthy Volunteers. Clin Pharmacol Ther. 2020;107:406\u201314.","journal-title":"Clin Pharmacol Ther"},{"key":"867_CR192","doi-asserted-by":"crossref","unstructured":"Weisel K, Scott N, Berger S, Wang S, Brown K, Powell M, Broer M, Watts C, Tompson DJ, Burriss SW, et al. A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis. BMJ Open Gastroenterol 2021;8:e000680","DOI":"10.1136\/bmjgast-2021-000680"},{"key":"867_CR193","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1111\/cts.13607","volume":"16","author":"NS Jones","year":"2023","unstructured":"Jones NS, Kshirsagar S, Mohanan V, Ramakrishnan V, Di Nucci F, Ma L, Mao J, Ding H, Klabunde S, Vucic D, et al. A phase I, randomized, ascending-dose study to assess safety, pharmacokinetics, and activity of GDC-8264, a RIP1 inhibitor, in healthy volunteers. Clin Transl Sci. 2023;16:1997\u20132009.","journal-title":"Clin Transl Sci"},{"key":"867_CR194","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41582-019-0301-2","volume":"16","author":"E Tolosa","year":"2020","unstructured":"Tolosa E, Vila M, Klein C, Rascol O. LRRK2 in Parkinson disease: challenges of clinical trials. Nat Rev Neurol. 2020;16:97\u2013107.","journal-title":"Nat Rev Neurol"},{"key":"867_CR195","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1523\/JNEUROSCI.5601-11.2012","volume":"32","author":"MS Moehle","year":"2012","unstructured":"Moehle MS, Webber PJ, Tse T, Sukar N, Standaert DG, DeSilva TM, Cowell RM, West AB. LRRK2 inhibition attenuates microglial inflammatory responses. J Neurosci. 2012;32:1602\u201311.","journal-title":"J Neurosci"},{"key":"867_CR196","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12974-015-0449-7","volume":"12","author":"I Russo","year":"2015","unstructured":"Russo I, Berti G, Plotegher N, Bernardo G, Filograna R, Bubacco L, Greggio E. Leucine-rich repeat kinase 2 positively regulates inflammation and down-regulates NF-kappaB p50 signaling in cultured microglia cells. J Neuroinflammation. 2015;12:230.","journal-title":"J Neuroinflammation"},{"key":"867_CR197","doi-asserted-by":"publisher","first-page":"eabp8869","DOI":"10.1126\/scitranslmed.abp8869","volume":"14","author":"RG Langston","year":"2022","unstructured":"Langston RG, Beilina A, Reed X, Kaganovich A, Singleton AB, Blauwendraat C, Gibbs JR, Cookson MR. Association of a common genetic variant with Parkinson\u2019s disease is mediated by microglia. Sci Transl Med. 2022;14:eabp8869.","journal-title":"Sci Transl Med"},{"key":"867_CR198","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/mds.29297","volume":"38","author":"D Jennings","year":"2023","unstructured":"Jennings D, Huntwork-Rodriguez S, Vissers M, Daryani VM, Diaz D, Goo MS, Chen JJ, Maciuca R, Fraser K, Mabrouk OS, et al. LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson\u2019s Disease. Mov Disord. 2023;38:386\u201398.","journal-title":"Mov Disord"},{"key":"867_CR199","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41531-023-00624-8","volume":"10","author":"Y Naaldijk","year":"2024","unstructured":"Naaldijk Y, Fernandez B, Fasiczka R, Fdez E, Leghay C, Croitoru I, Kwok JB, Boulesnane Y, Vizeneux A, Mutez E, et al. A potential patient stratification biomarker for Parkinson s disease based on LRRK2 kinase-mediated centrosomal alterations in peripheral blood-derived cells. NPJ Parkinsons Dis. 2024;10:12.","journal-title":"NPJ Parkinsons Dis"},{"key":"867_CR200","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41419-021-04002-1","volume":"12","author":"Z Lin","year":"2021","unstructured":"Lin Z, Chen C, Yang D, Ding J, Wang G, Ren H. DJ-1 inhibits microglial activation and protects dopaminergic neurons in vitro and in vivo through interacting with microglial p65. Cell Death Dis. 2021;12:715.","journal-title":"Cell Death Dis"},{"key":"867_CR201","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2013.08.007","volume":"60","author":"JH Kim","year":"2013","unstructured":"Kim JH, Choi DJ, Jeong HK, Kim J, Kim DW, Choi SY, Park SM, Suh YH, Jou I, Joe EH. DJ-1 facilitates the interaction between STAT1 and its phosphatase, SHP-1, in brain microglia and astrocytes: A novel anti-inflammatory function of DJ-1. Neurobiol Dis. 2013;60:1\u201310.","journal-title":"Neurobiol Dis"},{"key":"867_CR202","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/jnc.12633","volume":"129","author":"D Trudler","year":"2014","unstructured":"Trudler D, Weinreb O, Mandel SA, Youdim MB, Frenkel D. DJ-1 deficiency triggers microglia sensitivity to dopamine toward a pro-inflammatory phenotype that is attenuated by rasagiline. J Neurochem. 2014;129:434\u201347.","journal-title":"J Neurochem"},{"key":"867_CR203","unstructured":"Group F-NBW: FDA-NIH Biomarker Working Group BEST (Biomarkers, EndpointS, and Other Tools) Resource. Food and Drug Administration (US), Silver Spring, MD (2016) Co-published by National Institutes of Health (US): Bethesda (MD) (https:\/\/www.ncbinlmnihgov\/books\/NBK326791\/, consulted in February 2023) 2016."},{"key":"867_CR204","unstructured":"In BEST (Biomarkers, EndpointS, and other Tools) Resource. Silver Spring (MD) Bethesda (MD); 2016"},{"key":"867_CR205","doi-asserted-by":"publisher","first-page":"95","DOI":"10.4137\/BMI.S38440","volume":"11","author":"SI Sherwani","year":"2016","unstructured":"Sherwani SI, Khan HA, Ekhzaimy A, Masood A, Sakharkar MK. Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients. Biomark Insights. 2016;11:95\u2013104.","journal-title":"Biomark Insights"},{"key":"867_CR206","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.769335","volume":"8","author":"AM Cusumano","year":"2021","unstructured":"Cusumano AM, Tzanno-Martins C, Rosa-Diez GJ. The Glomerular Filtration Rate: From the Diagnosis of Kidney Function to a Public Health Tool. Front Med (Lausanne). 2021;8: 769335.","journal-title":"Front Med (Lausanne)"},{"key":"867_CR207","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13195-018-0392-9","volume":"10","author":"S Hsu","year":"2018","unstructured":"Hsu S, Gordon BA, Hornbeck R, Norton JB, Levitch D, Louden A, Ziegemeier E, Laforce R Jr, Chhatwal J, Day GS, et al. Discovery and validation of autosomal dominant Alzheimer\u2019s disease mutations. Alzheimer\u2019s research & therapy. 2018;10:67.","journal-title":"Alzheimer\u2019s research & therapy"},{"key":"867_CR208","doi-asserted-by":"publisher","first-page":"675","DOI":"10.3233\/JAD-200492","volume":"77","author":"S Fung","year":"2020","unstructured":"Fung S, Smith CL, Prater KE, Case A, Green K, Osnis L, Winston C, Kinoshita Y, Sopher B, Morrison RS, et al. Early-Onset Familial Alzheimer Disease Variant PSEN2 N141I Heterozygosity is Associated with Altered Microglia Phenotype. J Alzheimers Dis. 2020;77:675\u201388.","journal-title":"J Alzheimers Dis"},{"key":"867_CR209","doi-asserted-by":"crossref","unstructured":"Zhao A, Jiao Y, Ye G, Kang W, Tan L, Li Y, Deng Y, Liu J, Alzheimer\u2019s Disease Neuroimaging I. Soluble TREM2 levels associate with conversion from mild cognitive impairment to Alzheimer\u2019s disease. J Clin Invest 2022;132:e158708","DOI":"10.1172\/JCI158708"},{"key":"867_CR210","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S1474-4422(22)00027-8","volume":"21","author":"E Morenas-Rodriguez","year":"2022","unstructured":"Morenas-Rodriguez E, Li Y, Nuscher B, Franzmeier N, Xiong C, Suarez-Calvet M, Fagan AM, Schultz S, Gordon BA, Benzinger TLS, et al. Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer\u2019s disease: a longitudinal observational study. Lancet Neurol. 2022;21:329\u201341.","journal-title":"Lancet Neurol"},{"key":"867_CR211","doi-asserted-by":"publisher","first-page":"eabm5667","DOI":"10.1126\/sciadv.abm5667","volume":"8","author":"XL Bu","year":"2022","unstructured":"Bu XL, Sun PY, Fan DY, Wang J, Sun HL, Cheng Y, Zeng GH, Chen DW, Li HY, Yi X, et al. Associations of plasma soluble CD22 levels with brain amyloid burden and cognitive decline in Alzheimer\u2019s disease. Sci Adv. 2022;8:eabm5667.","journal-title":"Sci Adv"},{"key":"867_CR212","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack CR Jr, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, Hansson O, Ho C, Jagust W, McDade E, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. 2024;20:5143\u201369.","journal-title":"Alzheimers Dement"},{"key":"867_CR213","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.gendis.2021.12.015","volume":"10","author":"Y Huang","year":"2023","unstructured":"Huang Y, Wei J, Cooper A, Morris MJ. Parkinson\u2019s disease: From genetics to molecular dysfunction and targeted therapeutic approaches. Genes Dis. 2023;10:786\u201398.","journal-title":"Genes Dis"},{"key":"867_CR214","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12974-023-02776-z","volume":"20","author":"F Lind-Holm Mogensen","year":"2023","unstructured":"Lind-Holm Mogensen F, Scafidi A, Poli A, Michelucci A. PARK7\/DJ-1 in microglia: implications in Parkinson\u2019s disease and relevance as a therapeutic target. J Neuroinflammation. 2023;20:95.","journal-title":"J Neuroinflammation"},{"key":"867_CR215","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.neurobiolaging.2020.02.017","volume":"91","author":"Z Dwyer","year":"2020","unstructured":"Dwyer Z, Rudyk C, Thompson A, Farmer K, Fenner B, Fortin T, Derksen A, Sun H, Hayley S. Clint: Leucine-rich repeat kinase-2 (LRRK2) modulates microglial phenotype and dopaminergic neurodegeneration. Neurobiol Aging. 2020;91:45\u201355.","journal-title":"Neurobiol Aging"},{"key":"867_CR216","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41419-023-05672-9","volume":"14","author":"P Calabresi","year":"2023","unstructured":"Calabresi P, Mechelli A, Natale G, Volpicelli-Daley L, Di Lazzaro G, Ghiglieri V. Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis. 2023;14:176.","journal-title":"Cell Death Dis"},{"key":"867_CR217","doi-asserted-by":"publisher","DOI":"10.1016\/j.bionps.2023.100074","volume":"9","author":"KY Yamashita","year":"2023","unstructured":"Yamashita KY, Bhoopatiraju S, Silverglate BD, Grossberg GT. Biomarkers in Parkinson\u2019s disease: A state of the art review. Biomarkers in Neuropsychiatry. 2023;9: 100074.","journal-title":"Biomarkers in Neuropsychiatry"},{"key":"867_CR218","doi-asserted-by":"publisher","first-page":"6480","DOI":"10.1007\/s12035-017-0856-0","volume":"55","author":"C Maurel","year":"2018","unstructured":"Maurel C, Dangoumau A, Marouillat S, Brulard C, Chami A, Hergesheimer R, Corcia P, Blasco H, Andres CR. Vourc\u2019h P: Causative Genes in Amyotrophic Lateral Sclerosis and Protein Degradation Pathways: a Link to Neurodegeneration. Mol Neurobiol. 2018;55:6480\u201399.","journal-title":"Mol Neurobiol"},{"key":"867_CR219","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1007\/s00415-019-09363-4","volume":"266","author":"CV Greaves","year":"2019","unstructured":"Greaves CV, Rohrer JD. An update on genetic frontotemporal dementia. J Neurol. 2019;266:2075\u201386.","journal-title":"J Neurol"},{"key":"867_CR220","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00415-009-0131-z","volume":"256","author":"TS Reijn","year":"2009","unstructured":"Reijn TS, Abdo WF, Schelhaas HJ, Verbeek MM. CSF neurofilament protein analysis in the differential diagnosis of ALS. J Neurol. 2009;256:615\u20139.","journal-title":"J Neurol"},{"key":"867_CR221","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13024-024-00768-y","volume":"19","author":"EA Albagli","year":"2024","unstructured":"Albagli EA, Calliari A, Gendron TF, Zhang YJ. HDGFL2 cryptic protein: a portal to detection and diagnosis in neurodegenerative disease. Mol Neurodegener. 2024;19:79.","journal-title":"Mol Neurodegener"},{"key":"867_CR222","doi-asserted-by":"crossref","unstructured":"Suarez-Calvet M, Capell A, Araque Caballero MA, Morenas-Rodriguez E, Fellerer K, Franzmeier N, Kleinberger G, Eren E, Deming Y, Piccio L, et al. CSF progranulin increases in the course of Alzheimer\u2019s disease and is associated with sTREM2, neurodegeneration and cognitive decline. EMBO Mol Med. 2018;10:e9712.","DOI":"10.15252\/emmm.201809712"},{"key":"867_CR223","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.neurobiolaging.2019.12.012","volume":"88","author":"L Batzu","year":"2020","unstructured":"Batzu L, Westman E, Pereira JB. Alzheimer\u2019s Disease Neuroimaging I: Cerebrospinal fluid progranulin is associated with increased cortical thickness in early stages of Alzheimer\u2019s disease. Neurobiol Aging. 2020;88:61\u201370.","journal-title":"Neurobiol Aging"},{"key":"867_CR224","doi-asserted-by":"publisher","first-page":"709","DOI":"10.2174\/1567205017666201109095657","volume":"17","author":"A Kulczynska-Przybik","year":"2020","unstructured":"Kulczynska-Przybik A, Slowik A, Mroczko P, Borawski B, Groblewska M, Borawska R, Mroczko B. Cerebrospinal Fluid and Blood CX3CL1 as a Potential Biomarker in Early Diagnosis and Prognosis of Dementia. Curr Alzheimer Res. 2020;17:709\u201321.","journal-title":"Curr Alzheimer Res"},{"key":"867_CR225","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/S1474-4422(18)30490-3","volume":"18","author":"AM Arranz","year":"2019","unstructured":"Arranz AM, De Strooper B. The role of astroglia in Alzheimer\u2019s disease: pathophysiology and clinical implications. Lancet Neurol. 2019;18:406\u201314.","journal-title":"Lancet Neurol"},{"key":"867_CR226","doi-asserted-by":"crossref","unstructured":"Mavroudis I, Chowdhury R, Petridis F, Karantali E, Chatzikonstantinou S, Balmus IM, Luca IS, Ciobica A, Kazis D. YKL-40 as a potential biomarker for the differential diagnosis of Alzheimer\u2019s disease. Medicina (Kaunas, Lithuania). 2021;58:60.","DOI":"10.3390\/medicina58010060"},{"key":"867_CR227","doi-asserted-by":"publisher","first-page":"906","DOI":"10.2174\/1570159X15666170208124324","volume":"15","author":"P Muszy\u0144ski","year":"2017","unstructured":"Muszy\u0144ski P, Groblewska M, Kulczy\u0144ska-Przybik A, Ku\u0142akowska A, Mroczko B. YKL-40 as a potential biomarker and a possible target in therapeutic strategies of Alzheimer\u2019s disease. Curr Neuropharmacol. 2017;15:906\u201317.","journal-title":"Curr Neuropharmacol"},{"key":"867_CR228","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.jalz.2018.01.012","volume":"14","author":"CL Sutphen","year":"2018","unstructured":"Sutphen CL, McCue L, Herries EM, Xiong C, Ladenson JH, Holtzman DM, Fagan AM. Adni: Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer\u2019s disease. Alzheimers Dement. 2018;14:869\u201379.","journal-title":"Alzheimers Dement"},{"key":"867_CR229","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41467-023-44374-w","volume":"15","author":"N Franzmeier","year":"2024","unstructured":"Franzmeier N, Dehsarvi A, Steward A, Biel D, Dewenter A, Roemer SN, Wagner F, Gross M, Brendel M, Moscoso A, et al. Elevated CSF GAP-43 is associated with accelerated tau accumulation and spread in Alzheimer\u2019s disease. Nat Commun. 2024;15:202.","journal-title":"Nat Commun"},{"key":"867_CR230","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s00401-018-1851-x","volume":"136","author":"E Portelius","year":"2018","unstructured":"Portelius E, Olsson B, Hoglund K, Cullen NC, Kvartsberg H, Andreasson U, Zetterberg H, Sandelius A, Shaw LM, Lee VMY, et al. Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. Acta Neuropathol. 2018;136:363\u201376.","journal-title":"Acta Neuropathol"},{"key":"867_CR231","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13195-019-0564-2","volume":"11","author":"MTM Clarke","year":"2019","unstructured":"Clarke MTM, Brinkmalm A, Foiani MS, Woollacott IOC, Heller C, Heslegrave A, Keshavan A, Fox NC, Schott JM, Warren JD, et al. CSF synaptic protein concentrations are raised in those with atypical Alzheimer\u2019s disease but not frontotemporal dementia. Alzheimers Res Ther. 2019;11:105.","journal-title":"Alzheimers Res Ther"},{"key":"867_CR232","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41398-020-0801-2","volume":"10","author":"W Liu","year":"2020","unstructured":"Liu W, Lin H, He X, Chen L, Dai Y, Jia W, Xue X, Tao J, Chen L. Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer\u2019s disease and mild cognitive impairment. Transl Psychiatry. 2020;10:125.","journal-title":"Transl Psychiatry"},{"key":"867_CR233","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1136\/jnnp-2019-321954","volume":"91","author":"C Heller","year":"2020","unstructured":"Heller C, Foiani MS, Moore K, Convery R, Bocchetta M, Neason M, Cash DM, Thomas D, Greaves CV, Woollacott IO, et al. Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2020;91:263\u201370.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"867_CR234","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13195-020-00682-7","volume":"12","author":"IMW Verberk","year":"2020","unstructured":"Verberk IMW, Thijssen E, Koelewijn J, Mauroo K, Vanbrabant J, de Wilde A, Zwan MD, Verfaillie SCJ, Ossenkoppele R, Barkhof F, et al. Combination of plasma amyloid beta((1\u201342\/1-40)) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. Alzheimers Res Ther. 2020;12:118.","journal-title":"Alzheimers Res Ther"},{"key":"867_CR235","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1038\/s41591-023-02380-x","volume":"29","author":"B Bellaver","year":"2023","unstructured":"Bellaver B, Povala G, Ferreira PCL, Ferrari-Souza JP, Leffa DT, Lussier FZ, Benedet AL, Ashton NJ, Triana-Baltzer G, Kolb HC, et al. Astrocyte reactivity influences amyloid-\u03b2 effects on tau pathology in preclinical Alzheimer\u2019s disease. Nat Med. 2023;29:1775\u201381.","journal-title":"Nat Med"},{"key":"867_CR236","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s00404-010-1589-8","volume":"283","author":"F Gundogdu","year":"2011","unstructured":"Gundogdu F, Soylu F, Erkan L, Tatli O, Mavi S, Yavuzcan A. The role of serum CA-125 levels and CA-125 tissue expression positivity in the prediction of the recurrence of stage III and IV epithelial ovarian tumors (CA-125 levels and tissue CA-125 in ovarian tumors). Arch Gynecol Obstet. 2011;283:1397\u2013402.","journal-title":"Arch Gynecol Obstet"},{"key":"867_CR237","doi-asserted-by":"publisher","first-page":"4054","DOI":"10.1200\/JCO.2001.19.20.4054","volume":"19","author":"GJ Rustin","year":"2001","unstructured":"Rustin GJ, Marples M, Nelstrop AE, Mahmoudi M, Meyer T. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol. 2001;19:4054\u20137.","journal-title":"J Clin Oncol"},{"key":"867_CR238","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4103\/1673-5374.264444","volume":"15","author":"H Nakanishi","year":"2020","unstructured":"Nakanishi H. Microglial cathepsin B as a key driver of inflammatory brain diseases and brain aging. Neural Regen Res. 2020;15:25\u20139.","journal-title":"Neural Regen Res"},{"key":"867_CR239","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.yexcr.2017.11.015","volume":"362","author":"H Bai","year":"2018","unstructured":"Bai H, Yang B, Yu W, Xiao Y, Yu D, Zhang Q. Cathepsin B links oxidative stress to the activation of NLRP3 inflammasome. Exp Cell Res. 2018;362:180\u20137.","journal-title":"Exp Cell Res"},{"key":"867_CR240","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s10571-022-01216-5","volume":"43","author":"KV Do","year":"2023","unstructured":"Do KV, Hjorth E, Wang Y, Jun B, Kautzmann MI, Ohshima M, Eriksdotter M, Schultzberg M, Bazan NG. Cerebrospinal Fluid Profile of Lipid Mediators in Alzheimer\u2019s Disease. Cell Mol Neurobiol. 2023;43:797\u2013811.","journal-title":"Cell Mol Neurobiol"},{"key":"867_CR241","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1002\/alz.13676","volume":"20","author":"Y Jiang","year":"2024","unstructured":"Jiang Y, Uhm H, Ip FC, Ouyang L, Lo RMN, Cheng EYL, Cao X, Tan CMC, Law BCH, Ortiz-Romero P, et al. A blood-based multi-pathway biomarker assay for early detection and staging of Alzheimer\u2019s disease across ethnic groups. Alzheimers Dement. 2024;20:2000\u201315.","journal-title":"Alzheimers Dement"},{"key":"867_CR242","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.bbrc.2011.07.127","volume":"412","author":"K Ashutosh","year":"2011","unstructured":"Ashutosh K. W, Cotter R, Borgmann K, Wu L, Persidsky R, Sakhuja N, Ghorpade A: CXCL8 protects human neurons from amyloid-\u03b2-induced neurotoxicity: relevance to Alzheimer\u2019s disease. Biochem Biophys Res Commun. 2011;412:565\u201371.","journal-title":"Biochem Biophys Res Commun"},{"key":"867_CR243","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.neurobiolaging.2012.08.009","volume":"34","author":"T Kiyota","year":"2013","unstructured":"Kiyota T, Gendelman HE, Weir RA, Higgins EE, Zhang G, Jain M. CCL2 affects \u03b2-amyloidosis and progressive neurocognitive dysfunction in a mouse model of Alzheimer\u2019s disease. Neurobiol Aging. 2013;34:1060\u20138.","journal-title":"Neurobiol Aging"},{"key":"867_CR244","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, Shcherbinin S, Sparks J, Sims JR, Brys M, et al. Donanemab in Early Alzheimer\u2019s Disease. N Engl J Med. 2021;384:1691\u2013704.","journal-title":"N Engl J Med"},{"key":"867_CR245","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, et al. Lecanemab in Early Alzheimer\u2019s Disease. N Engl J Med. 2023;388:9\u201321.","journal-title":"N Engl J Med"},{"key":"867_CR246","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.852003","volume":"13","author":"S Menon","year":"2022","unstructured":"Menon S, Armstrong S, Hamzeh A, Visanji NP, Sardi SP, Tandon A. Alpha-Synuclein targeting therapeutics for Parkinson\u2019s disease and related synucleinopathies. Front Neurol. 2022;13: 852003.","journal-title":"Front Neurol"},{"key":"867_CR247","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1136\/jnnp-2017-317138","volume":"89","author":"P Steinacker","year":"2018","unstructured":"Steinacker P, Verde F, Fang L, Feneberg E, Oeckl P, Roeber S, Anderl-Straub S, Danek A, Diehl-Schmid J, Fassbender K, et al. Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. J Neurol Neurosurg Psychiatry. 2018;89:239\u201347.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"867_CR248","first-page":"1338","volume":"90","author":"B Gille","year":"2019","unstructured":"Gille B, De Schaepdryver M, Dedeene L, Goossens J, Claeys KG, Van Den Bosch L, Tournoy J, Van Damme P, Poesen K. Inflammatory markers in cerebrospinal fluid: independent prognostic biomarkers in amyotrophic lateral sclerosis? J Neurol Neurosurg Psychiatry. 2019;90:1338\u201346.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"867_CR249","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/acn3.51078","volume":"7","author":"F Huang","year":"2020","unstructured":"Huang F, Zhu Y, Hsiao-Nakamoto J, Tang X, Dugas JC, Moscovitch-Lopatin M, Glass JD, Brown RH Jr, Ladha SS, Lacomis D, et al. Longitudinal biomarkers in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2020;7:1103\u201316.","journal-title":"Ann Clin Transl Neurol"},{"key":"867_CR250","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12974-015-0350-4","volume":"12","author":"J Ehrhart","year":"2015","unstructured":"Ehrhart J, Smith AJ, Kuzmin-Nichols N, Zesiewicz TA, Jahan I, Shytle RD, Kim SH, Sanberg CD, Vu TH, Gooch CL, et al. Humoral factors in ALS patients during disease progression. J Neuroinflammation. 2015;12:127.","journal-title":"J Neuroinflammation"},{"key":"867_CR251","first-page":"87","volume":"7","author":"R Mashima","year":"2016","unstructured":"Mashima R, Sakai E, Tanaka M, Kosuga M, Okuyama T. The levels of urinary glycosaminoglycans of patients with attenuated and severe type of mucopolysaccharidosis II determined by liquid chromatography-tandem mass spectrometry. Mol Genet Metab Rep. 2016;7:87\u201391.","journal-title":"Mol Genet Metab Rep"},{"key":"867_CR252","doi-asserted-by":"crossref","unstructured":"Salerno S, Viviano M, Baglini E, Poggetti V, Giorgini D, Castagnoli J, Barresi E, Castellano S, Da Settimo F, Taliani S: TSPO Radioligands for Neuroinflammation: An Overview. Molecules 2024;29:4212.","DOI":"10.3390\/molecules29174212"},{"key":"867_CR253","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1007\/s12035-021-02348-3","volume":"58","author":"PF Zhang","year":"2021","unstructured":"Zhang PF, Hu H, Tan L, Yu JT. Microglia Biomarkers in Alzheimer\u2019s Disease. Mol Neurobiol. 2021;58:3388\u2013404.","journal-title":"Mol Neurobiol"},{"key":"867_CR254","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.neurobiolaging.2018.10.022","volume":"74","author":"BS Rauchmann","year":"2019","unstructured":"Rauchmann BS, Schneider-Axmann T, Alexopoulos P, Perneczky R. CSF soluble TREM2 as a measure of immune response along the Alzheimer\u2019s disease continuum. Neurobiol Aging. 2019;74:182\u201390.","journal-title":"Neurobiol Aging"},{"key":"867_CR255","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00401-018-1932-x","volume":"136","author":"JL Molinuevo","year":"2018","unstructured":"Molinuevo JL, Ayton S, Batrla R, Bednar MM, Bittner T, Cummings J, Fagan AM, Hampel H, Mielke MM, Mikulskis A, et al. Current state of Alzheimer\u2019s fluid biomarkers. Acta Neuropathol. 2018;136:821\u201353.","journal-title":"Acta Neuropathol"},{"key":"867_CR256","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.neurobiolaging.2013.09.035","volume":"35","author":"W Kamphuis","year":"2014","unstructured":"Kamphuis W, Middeldorp J, Kooijman L, Sluijs JA, Kooi EJ, Moeton M, Freriks M, Mizee MR, Hol EM. Glial fibrillary acidic protein isoform expression in plaque related astrogliosis in Alzheimer\u2019s disease. Neurobiol Aging. 2014;35:492\u2013510.","journal-title":"Neurobiol Aging"},{"key":"867_CR257","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","volume":"387","author":"TM Miller","year":"2022","unstructured":"Miller TM, Cudkowicz ME, Genge A, Shaw PJ, Sobue G, Bucelli RC, Chio A, Van Damme P, Ludolph AC, Glass JD, et al. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2022;387:1099\u2013110.","journal-title":"N Engl J Med"},{"key":"867_CR258","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.1172\/JCI99081","volume":"128","author":"A McCampbell","year":"2018","unstructured":"McCampbell A, Cole T, Wegener AJ, Tomassy GS, Setnicka A, Farley BJ, Schoch KM, Hoye ML, Shabsovich M, Sun L, et al. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. J Clin Invest. 2018;128:3558\u201367.","journal-title":"J Clin Invest"},{"key":"867_CR259","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/jamaneurol.2013.593","volume":"70","author":"L Winer","year":"2013","unstructured":"Winer L, Srinivasan D, Chun S, Lacomis D, Jaffa M, Fagan A, Holtzman DM, Wancewicz E, Bennett CF, Bowser R, et al. SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy. JAMA Neurol. 2013;70:201\u20137.","journal-title":"JAMA Neurol"},{"key":"867_CR260","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1038\/s41467-022-30387-4","volume":"13","author":"G Krishnan","year":"2022","unstructured":"Krishnan G, Raitcheva D, Bartlett D, Prudencio M, McKenna-Yasek DM, Douthwright C, Oskarsson BE, Ladha S, King OD, Barmada SJ, et al. Poly(GR) and poly(GA) in cerebrospinal fluid as potential biomarkers for C9ORF72-ALS\/FTD. Nat Commun. 2022;13:2799.","journal-title":"Nat Commun"},{"key":"867_CR261","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41591-021-01557-6","volume":"28","author":"H Tran","year":"2022","unstructured":"Tran H, Moazami MP, Yang H, McKenna-Yasek D, Douthwright CL, Pinto C, Metterville J, Shin M, Sanil N, Dooley C, et al. Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide. Nat Med. 2022;28:117\u201324.","journal-title":"Nat Med"},{"key":"867_CR262","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","volume":"366","author":"J Ledermann","year":"2012","unstructured":"Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366:1382\u201392.","journal-title":"N Engl J Med"},{"key":"867_CR263","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330:512\u201327.","journal-title":"JAMA"},{"key":"867_CR264","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0025-6196(11)62406-3","volume":"76","author":"SG Roberts","year":"2001","unstructured":"Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc. 2001;76:576\u201381.","journal-title":"Mayo Clin Proc"},{"key":"867_CR265","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/jamaneurol.2015.3037","volume":"73","author":"H Zetterberg","year":"2016","unstructured":"Zetterberg H, Skillb\u00e4ck T, Mattsson N, Trojanowski JQ, Portelius E, Shaw LM, Weiner MW, Blennow K. Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. JAMA Neurol. 2016;73:60\u20137.","journal-title":"JAMA Neurol"},{"key":"867_CR266","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/s41591-021-01348-z","volume":"27","author":"S Palmqvist","year":"2021","unstructured":"Palmqvist S, Tideman P, Cullen N, Zetterberg H, Blennow K, Dage JL, Stomrud E, Janelidze S, Mattsson-Carlgren N, Hansson O. Prediction of future Alzheimer\u2019s disease dementia using plasma phospho-tau combined with other accessible measures. Nat Med. 2021;27:1034\u201342.","journal-title":"Nat Med"},{"key":"867_CR267","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, Chai X, Proctor NK, Eichenlaub U, Zetterberg H, et al. Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat Med. 2020;26:379\u201386.","journal-title":"Nat Med"},{"key":"867_CR268","doi-asserted-by":"crossref","unstructured":"Zhao A, Jiao Y, Ye G, Kang W, Tan L, Li Y, Deng Y, Liu J. Soluble TREM2 levels associate with conversion from mild cognitive impairment to Alzheimer\u2019s disease. J Clin Inv. 2022;132:e158708.","DOI":"10.1172\/JCI158708"},{"key":"867_CR269","doi-asserted-by":"publisher","first-page":"e1315","DOI":"10.1212\/WNL.0000000000200035","volume":"98","author":"JL Ebenau","year":"2022","unstructured":"Ebenau JL, Pelkmans W, Verberk IMW, Verfaillie SCJ, van den Bosch KA, van Leeuwenstijn M, Collij LE, Scheltens P, Prins ND, Barkhof F, et al. Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline. Neurology. 2022;98:e1315\u201326.","journal-title":"Neurology"},{"key":"867_CR270","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1212\/WNL.0b013e318248e568","volume":"78","author":"R Tarawneh","year":"2012","unstructured":"Tarawneh R, Lee JM, Ladenson JH, Morris JC, Holtzman DM. CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease. Neurology. 2012;78:709\u201319.","journal-title":"Neurology"},{"key":"867_CR271","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13195-015-0142-1","volume":"7","author":"MI Kester","year":"2015","unstructured":"Kester MI, Teunissen CE, Sutphen C, Herries EM, Ladenson JH, Xiong C, Scheltens P, van der Flier WM, Morris JC, Holtzman DM, Fagan AM. Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer\u2019s disease in a memory clinic cohort. Alzheimers Res Ther. 2015;7:59.","journal-title":"Alzheimers Res Ther"},{"key":"867_CR272","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.jalz.2018.03.005","volume":"14","author":"R Brookmeyer","year":"2018","unstructured":"Brookmeyer R, Abdalla N. Estimation of lifetime risks of Alzheimer\u2019s disease dementia using biomarkers for preclinical disease. Alzheimer\u2019s & dementia\u202f: the journal of the Alzheimer\u2019s Association. 2018;14:981\u20138.","journal-title":"Alzheimer\u2019s & dementia : the journal of the Alzheimer\u2019s Association"},{"key":"867_CR273","first-page":"162","volume":"10","author":"CC Pedersen","year":"2024","unstructured":"Pedersen CC, Ushakova A, Alves G, Tysnes O-B, Blennow K, Zetterberg H, Maple-Gr\u00f8dem J, Lange J. Serum neurofilament light at diagnosis: a prognostic indicator for accelerated disease progression in Parkinson\u2019s Disease. npj\u00a0Parkinson\u2019s Disease. 2024;10:162.","journal-title":"npj\u00a0Parkinson\u2019s Disease"},{"key":"867_CR274","first-page":"48","volume":"10","author":"N Che","year":"2024","unstructured":"Che N, Ou R, Li C, Zhang L, Wei Q, Wang S, Jiang Q, Yang T, Xiao Y, Lin J, et al. Plasma GFAP as a prognostic biomarker of motor subtype in early Parkinson\u2019s disease. npj\u00a0Parkinson\u2019s Disease. 2024;10:48.","journal-title":"npj\u00a0Parkinson\u2019s Disease."},{"key":"867_CR275","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1212\/WNL.0000000000001642","volume":"84","author":"CH Lu","year":"2015","unstructured":"Lu CH, Macdonald-Wallis C, Gray E, Pearce N, Petzold A, Norgren N, Giovannoni G, Fratta P, Sidle K, Fish M, et al. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015;84:2247\u201357.","journal-title":"Neurology"},{"key":"867_CR276","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s00415-020-09761-z","volume":"267","author":"S Abu-Rumeileh","year":"2020","unstructured":"Abu-Rumeileh S, Vacchiano V, Zenesini C, Polischi B, de Pasqua S, Fileccia E, Mammana A, Di Stasi V, Capellari S, Salvi F, et al. Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis. J Neurol. 2020;267:1699\u2013708.","journal-title":"J Neurol"},{"key":"867_CR277","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/ene.14063","volume":"27","author":"E Thouvenot","year":"2020","unstructured":"Thouvenot E, Demattei C, Lehmann S, Maceski-Maleska A, Hirtz C, Juntas-Morales R, Pageot N, Esselin F, Alphandery S, Vincent T, Camu W. Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis. Eur J Neurol. 2020;27:251\u20137.","journal-title":"Eur J Neurol"},{"key":"867_CR278","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.753242","volume":"13","author":"V Vacchiano","year":"2021","unstructured":"Vacchiano V, Mastrangelo A, Zenesini C, Masullo M, Quadalti C, Avoni P, Polischi B, Cherici A, Capellari S, Salvi F, et al. Plasma and CSF Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: A Cross-Sectional and Longitudinal Study. Front Aging Neurosci. 2021;13: 753242.","journal-title":"Front Aging Neurosci"},{"key":"867_CR279","doi-asserted-by":"publisher","first-page":"3608","DOI":"10.1111\/jcmm.17232","volume":"26","author":"C Zecca","year":"2022","unstructured":"Zecca C, Dell\u2019Abate MT, Pasculli G, Capozzo R, Barone R, Arima S, Pollice A, Brescia V, Tortelli R, Logroscino G. Role of plasma phosphorylated neurofilament heavy chain (pNfH) in amyotrophic lateral sclerosis. J Cell Mol Med. 2022;26:3608\u201315.","journal-title":"J Cell Mol Med"},{"key":"867_CR280","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1007\/s00415-020-09838-9","volume":"267","author":"YM Falzone","year":"2020","unstructured":"Falzone YM, Domi T, Agosta F, Pozzi L, Schito P, Fazio R, Del Carro U, Barbieri A, Comola M, Leocani L, et al. Serum phosphorylated neurofilament heavy-chain levels reflect phenotypic heterogeneity and are an independent predictor of survival in motor neuron disease. J Neurol. 2020;267:2272\u201380.","journal-title":"J Neurol"},{"key":"867_CR281","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.2217\/14622416.9.10.1543","volume":"9","author":"PB Ferrell Jr","year":"2008","unstructured":"Ferrell PB Jr, McLeod HL. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics. 2008;9:1543\u20136.","journal-title":"Pharmacogenomics"},{"key":"867_CR282","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1161\/STROKEAHA.121.036873","volume":"53","author":"L Sveikata","year":"2022","unstructured":"Sveikata L, Charidimou A, Viswanathan A. Vessels Sing Their ARIAs: The Role of Vascular Amyloid in the Age of Aducanumab. Stroke. 2022;53:298\u2013302.","journal-title":"Stroke"},{"key":"867_CR283","doi-asserted-by":"crossref","unstructured":"Sin MK, Zamrini E, Ahmed A, Nho K, Hajjar I. Anti-Amyloid Therapy, AD, and ARIA: Untangling the Role of CAA. J Clin Med 2023;12:6792.","DOI":"10.3390\/jcm12216792"},{"key":"867_CR284","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1093\/hmg\/3.4.569","volume":"3","author":"MC Chartier-Harlin","year":"1994","unstructured":"Chartier-Harlin MC, Parfitt M, Legrain S, Perez-Tur J, Brousseau T, Evans A, Berr C, Vidal O, Roques P, Gourlet V, et al. Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer\u2019s disease: analysis of the 19q13.2 chromosomal region. Hum Mol Genet. 1994;3:569\u201374.","journal-title":"Hum Mol Genet"},{"key":"867_CR285","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/mp.2011.52","volume":"16","author":"E Genin","year":"2011","unstructured":"Genin E, Hannequin D, Wallon D, Sleegers K, Hiltunen M, Combarros O, Bullido MJ, Engelborghs S, De Deyn P, Berr C, et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry. 2011;16:903\u20137.","journal-title":"Mol Psychiatry"},{"key":"867_CR286","doi-asserted-by":"crossref","unstructured":"Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. Jama 1997, 278:1349\u20131356.","DOI":"10.1001\/jama.1997.03550160069041"},{"key":"867_CR287","doi-asserted-by":"crossref","unstructured":"Kweon SH, Ryu HG, Park H, Lee S, Kim N, Kwon SH, Ma SX, Kim S, Ko HS. Linking Gba1 E326K mutation to microglia activation and mild age-dependent dopaminergic Neurodegeneration. bioRxiv 2024.","DOI":"10.1101\/2023.09.14.557673"},{"key":"867_CR288","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/ana.25276","volume":"84","author":"M Benatar","year":"2018","unstructured":"Benatar M, Wuu J, Andersen PM, Lombardi V, Malaspina A. Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol. 2018;84:130\u20139.","journal-title":"Ann Neurol"},{"key":"867_CR289","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/S1474-4422(19)30354-0","volume":"18","author":"EL van der Ende","year":"2019","unstructured":"van der Ende EL, Meeter LH, Poos JM, Panman JL, Jiskoot LC, Dopper EGP, Papma JM, de Jong FJ, Verberk IMW, Teunissen C, et al. Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurol. 2019;18:1103\u201311.","journal-title":"Lancet Neurol"},{"key":"867_CR290","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1002\/acn3.50890","volume":"6","author":"M De Schaepdryver","year":"2019","unstructured":"De Schaepdryver M, Goossens J, De Meyer S, Jeromin A, Masrori P, Brix B, Claeys KG, Schaeverbeke J, Adamczuk K, Vandenberghe R, et al. Serum neurofilament heavy chains as early marker of motor neuron degeneration. Ann Clin Transl Neurol. 2019;6:1971\u20139.","journal-title":"Ann Clin Transl Neurol"},{"key":"867_CR291","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/14728222.2020.1738390","volume":"24","author":"E Abati","year":"2020","unstructured":"Abati E, Bresolin N, Comi G, Corti S. Silence superoxide dismutase 1 (SOD1): a promising therapeutic target for amyotrophic lateral sclerosis (ALS). Expert Opin Ther Targets. 2020;24:295\u2013310.","journal-title":"Expert Opin Ther Targets"},{"key":"867_CR292","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.neuron.2011.09.011","volume":"72","author":"M DeJesus-Hernandez","year":"2011","unstructured":"DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245\u201356.","journal-title":"Neuron"},{"key":"867_CR293","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.neuron.2011.09.010","volume":"72","author":"AE Renton","year":"2011","unstructured":"Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, Schymick JC, Laaksovirta H, van Swieten JC, Myllykangas L, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257\u201368.","journal-title":"Neuron"},{"key":"867_CR294","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/nature09320","volume":"466","author":"AC Elden","year":"2010","unstructured":"Elden AC, Kim HJ, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, Armakola M, Geser F, Greene R, Lu MM, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466:1069\u201375.","journal-title":"Nature"},{"key":"867_CR295","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/cpt.2554","volume":"112","author":"E Bakker","year":"2022","unstructured":"Bakker E, Hendrikse NM, Ehmann F, van der Meer DS, Llinares Garcia J, Vetter T, Starokozhko V, Mol PGM. Biomarker Qualification at the European Medicines Agency: A Review of Biomarker Qualification Procedures From 2008 to 2020. Clin Pharmacol Ther. 2022;112:69\u201380.","journal-title":"Clin Pharmacol Ther"},{"key":"867_CR296","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/s41582-023-00891-2","volume":"19","author":"R McMackin","year":"2023","unstructured":"McMackin R, Bede P, Ingre C, Malaspina A, Hardiman O. Biomarkers in amyotrophic lateral sclerosis: current status and future prospects. Nat Rev Neurol. 2023;19:754\u201368.","journal-title":"Nat Rev Neurol"},{"key":"867_CR297","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-023-02443-z","volume":"29","author":"K Horie","year":"2023","unstructured":"Horie K, Salvado G, Barthelemy NR, Janelidze S, Li Y, He Y, Saef B, Chen CD, Jiang H, Strandberg O, et al. CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer\u2019s disease. Nat Med. 2023;29:1954\u201363.","journal-title":"Nat Med"},{"key":"867_CR298","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13195-019-0562-4","volume":"12","author":"S Abu-Rumeileh","year":"2019","unstructured":"Abu-Rumeileh S, Steinacker P, Polischi B, Mammana A, Bartoletti-Stella A, Oeckl P, Baiardi S, Zenesini C, Huss A, Cortelli P, et al. CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia. Alzheimers Res Ther. 2019;12:2.","journal-title":"Alzheimers Res Ther"},{"key":"867_CR299","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2025.120248","volume":"572","author":"L Agnello","year":"2025","unstructured":"Agnello L, Gambino CM, Ciaccio AM, Salemi G, Brighina F, Ragonese P, Piccoli T, Blandino V, Di Stefano V, Cacciabaudo F, et al. The value of serum glial fibrillary acidic protein as a biomarker of astrogliosis in different neurological diseases. Clin Chim Acta. 2025;572: 120248.","journal-title":"Clin Chim Acta"},{"key":"867_CR300","doi-asserted-by":"crossref","unstructured":"Grillo P, Riboldi GM, Pisani A, Kang UJ, Fereshtehnejad SM: Amplification parameters of the alpha-synuclein seed amplification assay on CSF predict the clinical subtype of Parkinson\u2019s Disease at 10-year follow-up. medRxiv 2025.","DOI":"10.1101\/2025.03.27.25324778"},{"key":"867_CR301","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/mdc3.13710","volume":"10","author":"A Grossauer","year":"2023","unstructured":"Grossauer A, Hemicker G, Krismer F, Peball M, Djamshidian A, Poewe W, Seppi K, Heim B. alpha-Synuclein Seed Amplification Assays in the Diagnosis of Synucleinopathies Using Cerebrospinal Fluid-A Systematic Review and Meta-Analysis. Mov Disord Clin Pract. 2023;10:737\u201347.","journal-title":"Mov Disord Clin Pract"},{"key":"867_CR302","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41591-023-02788-5","volume":"30","author":"KE Irwin","year":"2024","unstructured":"Irwin KE, Jasin P, Braunstein KE, Sinha IR, Garret MA, Bowden KD, Chang K, Troncoso JC, Moghekar A, Oh ES, et al. A fluid biomarker reveals loss of TDP-43 splicing repression in presymptomatic ALS-FTD. Nat Med. 2024;30:382\u201393.","journal-title":"Nat Med"},{"key":"867_CR303","doi-asserted-by":"crossref","unstructured":"Cordts I, Wachinger A, Scialo C, Lingor P, Polymenidou M, Buratti E, Feneberg E. TDP-43 Proteinopathy Specific Biomarker Development. Cells 2023;12:597.","DOI":"10.3390\/cells12040597"},{"key":"867_CR304","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1093\/brain\/awae032","volume":"147","author":"J Nilsson","year":"2024","unstructured":"Nilsson J, Pichet Binette A, Palmqvist S, Brum WS, Janelidze S, Ashton NJ, Spotorno N, Stomrud E, Gobom J, Zetterberg H, et al. Cerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseases. Brain. 2024;147:2414\u201327.","journal-title":"Brain"},{"key":"867_CR305","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13024-023-00657-w","volume":"18","author":"I Pesamaa","year":"2023","unstructured":"Pesamaa I, Muller SA, Robinson S, Darcher A, Paquet D, Zetterberg H, Lichtenthaler SF, Haass C. A microglial activity state biomarker panel differentiates FTD-granulin and Alzheimer\u2019s disease patients from controls. Mol Neurodegener. 2023;18:70.","journal-title":"Mol Neurodegener"},{"key":"867_CR306","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202012921","volume":"12","author":"M Suarez-Calvet","year":"2020","unstructured":"Suarez-Calvet M, Karikari TK, Ashton NJ, Lantero Rodriguez J, Mila-Aloma M, Gispert JD, Salvado G, Minguillon C, Fauria K, Shekari M, et al. Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer\u2019s continuum when only subtle changes in Abeta pathology are detected. EMBO Mol Med. 2020;12: e12921.","journal-title":"EMBO Mol Med"},{"key":"867_CR307","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14565","volume":"21","author":"YS Lin","year":"2025","unstructured":"Lin YS, Kwon HS, Lee WJ, Hwang M, Jeong JH, Koh SH, Choi SH, Fuh JL. Cross-cultural validation of plasma p-tau217 and p-tau181 as precision biomarkers for amyloid PET positivity: An East Asian study in Taiwan and Korea. Alzheimers Dement. 2025;21: e14565.","journal-title":"Alzheimers Dement"},{"key":"867_CR308","doi-asserted-by":"publisher","first-page":"8074","DOI":"10.1002\/alz.14315","volume":"20","author":"SE Schindler","year":"2024","unstructured":"Schindler SE, Petersen KK, Saef B, Tosun D, Shaw LM, Zetterberg H, Dage JL, Ferber K, Triana-Baltzer G, Du-Cuny L, et al. Head-to-head comparison of leading blood tests for Alzheimer\u2019s disease pathology. Alzheimers Dement. 2024;20:8074\u201396.","journal-title":"Alzheimers Dement"},{"key":"867_CR309","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","volume":"30","author":"NR Barthelemy","year":"2024","unstructured":"Barthelemy NR, Salvado G, Schindler SE, He Y, Janelidze S, Collij LE, Saef B, Henson RL, Chen CD, Gordon BA, et al. Highly accurate blood test for Alzheimer\u2019s disease is similar or superior to clinical cerebrospinal fluid tests. Nat Med. 2024;30:1085\u201395.","journal-title":"Nat Med"},{"key":"867_CR310","doi-asserted-by":"publisher","first-page":"4641","DOI":"10.1002\/alz.13054","volume":"19","author":"HS Kwon","year":"2023","unstructured":"Kwon HS, Kim JY, Koh SH, Choi SH, Lee EH, Jeong JH, Jang JW, Park KW, Kim EJ, Hong JY, et al. Predicting cognitive stage transition using p-tau181, Centiloid, and other measures. Alzheimers Dement. 2023;19:4641\u201350.","journal-title":"Alzheimers Dement"},{"key":"867_CR311","doi-asserted-by":"publisher","first-page":"7791","DOI":"10.1038\/s41598-025-90232-8","volume":"15","author":"HS Kwon","year":"2025","unstructured":"Kwon HS, Hwang M, Koh SH, Choi SH, Lee JH, Kim HJ, Park SH, Park HH, Jeong JH, Han MH, Kim JY. Comparison of plasma p-tau217 and p-tau181 in predicting amyloid positivity and prognosis among Korean memory clinic patients. Sci Rep. 2025;15:7791.","journal-title":"Sci Rep"},{"key":"867_CR312","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","volume":"28","author":"NJ Ashton","year":"2022","unstructured":"Ashton NJ, Janelidze S, Mattsson-Carlgren N, Binette AP, Strandberg O, Brum WS, Karikari TK, Gonzalez-Ortiz F, Di Molfetta G, Meda FJ, et al. Differential roles of Abeta42\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring. Nat Med. 2022;28:2555\u201362.","journal-title":"Nat Med"},{"key":"867_CR313","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/jamaneurol.2022.4485","volume":"80","author":"J Therriault","year":"2023","unstructured":"Therriault J, Vermeiren M, Servaes S, Tissot C, Ashton NJ, Benedet AL, Karikari TK, Lantero-Rodriguez J, Brum WS, Lussier FZ, et al. Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography. JAMA Neurol. 2023;80:188\u201399.","journal-title":"JAMA Neurol"},{"key":"867_CR314","doi-asserted-by":"crossref","unstructured":"Horie K, Salvado G, Koppisetti RK, Janelidze S, Barthelemy NR, He Y, Sato C, Gordon BA, Jiang H, Benzinger TLS, et al. Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer\u2019s disease. Nat Med 2025.","DOI":"10.1038\/s41591-025-03617-7"},{"key":"867_CR315","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","volume":"14","author":"M Khalil","year":"2018","unstructured":"Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, Barro C, Kappos L, Comabella M, Fazekas F, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14:577\u201389.","journal-title":"Nat Rev Neurol"},{"key":"867_CR316","doi-asserted-by":"crossref","unstructured":"Lambertsen KL, Soares CB, Gaist D, Nielsen HH. Neurofilaments: The C-Reactive Protein of Neurology. Brain sciences 2020;10:56.","DOI":"10.3390\/brainsci10010056"},{"key":"867_CR317","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13195-021-00953-x","volume":"14","author":"E-H Lee","year":"2022","unstructured":"Lee E-H, Kwon HS, Koh S-H, Choi SH, Jin J-H, Jeong JH, Jang J-W, Park KW, Kim E-J, Kim HJ, et al. Serum neurofilament light chain level as a predictor of cognitive stage transition. Alzheimer\u2019s Research & Therapy. 2022;14:6.","journal-title":"Alzheimer\u2019s Research & Therapy"},{"key":"867_CR318","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1007\/s13311-022-01237-4","volume":"19","author":"M Benatar","year":"2022","unstructured":"Benatar M, Wuu J, Andersen PM, Bucelli RC, Andrews JA, Otto M, Farahany NA, Harrington EA, Chen W, Mitchell AA, et al. Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study. Neurotherapeutics. 2022;19:1248\u201358.","journal-title":"Neurotherapeutics"},{"key":"867_CR319","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3988\/jcn.2022.0340","volume":"20","author":"TA Beltran","year":"2024","unstructured":"Beltran TA. Normative Values for Serum Neurofilament Light Chain in US Adults. J Clin Neurol. 2024;20:46\u20139.","journal-title":"J Clin Neurol"},{"key":"867_CR320","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/acn3.50972","volume":"7","author":"A Manouchehrinia","year":"2020","unstructured":"Manouchehrinia A, Piehl F, Hillert J, Kuhle J, Alfredsson L, Olsson T, Kockum I. Confounding effect of blood volume and body mass index on blood neurofilament light chain levels. Ann Clin Transl Neurol. 2020;7:139\u201343.","journal-title":"Ann Clin Transl Neurol"},{"key":"867_CR321","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40035-021-00257-y","volume":"10","author":"S Witzel","year":"2021","unstructured":"Witzel S, Frauhammer F, Steinacker P, Devos D, Pradat PF, Meininger V, Halbgebauer S, Oeckl P, Schuster J, Anders S, et al. Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis: development and validation of a prediction model to improve interventional trials. Transl Neurodegener. 2021;10:31.","journal-title":"Transl Neurodegener"},{"key":"867_CR322","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1038\/s41593-021-00936-z","volume":"24","author":"I Magen","year":"2021","unstructured":"Magen I, Yacovzada NS, Yanowski E, Coenen-Stass A, Grosskreutz J, Lu CH, Greensmith L, Malaspina A, Fratta P, Hornstein E. Circulating miR-181 is a prognostic biomarker for amyotrophic lateral sclerosis. Nat Neurosci. 2021;24:1534\u201341.","journal-title":"Nat Neurosci"},{"key":"867_CR323","unstructured":"Gendron TF, Chew J, Stankowski JN, Hayes LR, Zhang YJ, Prudencio M, Carlomagno Y, Daughrity LM, Jansen-West K, Perkerson EA, et al. Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis. Sci Transl Med 2017;9:eaai7886."},{"key":"867_CR324","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1038\/s41591-023-02380-x","volume":"29","author":"B Bellaver","year":"2023","unstructured":"Bellaver B, Povala G, Ferreira PCL, Ferrari-Souza JP, Leffa DT, Lussier FZ, Benedet AL, Ashton NJ, Triana-Baltzer G, Kolb HC, et al. Astrocyte reactivity influences amyloid-beta effects on tau pathology in preclinical Alzheimer\u2019s disease. Nat Med. 2023;29:1775\u201381.","journal-title":"Nat Med"},{"key":"867_CR325","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1186\/s12916-023-03120-1","volume":"21","author":"J Lin","year":"2023","unstructured":"Lin J, Ou R, Li C, Hou Y, Zhang L, Wei Q, Pang D, Liu K, Jiang Q, Yang T, et al. Plasma glial fibrillary acidic protein as a biomarker of disease progression in Parkinson\u2019s disease: a prospective cohort study. BMC Med. 2023;21:420.","journal-title":"BMC Med"},{"key":"867_CR326","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/acn3.51708","volume":"10","author":"F Verde","year":"2023","unstructured":"Verde F, Milone I, Maranzano A, Colombo E, Torre S, Solca F, Doretti A, Gentile F, Manini A, Bonetti R, et al. Serum levels of glial fibrillary acidic protein in patients with amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2023;10:118\u201329.","journal-title":"Ann Clin Transl Neurol"},{"key":"867_CR327","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1126\/science.1134108","volume":"314","author":"M Neumann","year":"2006","unstructured":"Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130\u20133.","journal-title":"Science"},{"key":"867_CR328","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1093\/brain\/awz099","volume":"142","author":"PT Nelson","year":"2019","unstructured":"Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K, Rademakers R, Alafuzoff I, Attems J, Brayne C, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142:1503\u201327.","journal-title":"Brain"},{"key":"867_CR329","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13024-021-00503-x","volume":"16","author":"A Meneses","year":"2021","unstructured":"Meneses A, Koga S, O\u2019Leary J, Dickson DW, Bu G, Zhao N. TDP-43 Pathology in Alzheimer\u2019s Disease. Mol Neurodegener. 2021;16:84.","journal-title":"Mol Neurodegener"},{"key":"867_CR330","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3109\/17482968.2010.541263","volume":"12","author":"Y Noto","year":"2011","unstructured":"Noto Y, Shibuya K, Sato Y, Kanai K, Misawa S, Sawai S, Mori M, Uchiyama T, Isose S, Nasu S, et al. Elevated CSF TDP-43 levels in amyotrophic lateral sclerosis: specificity, sensitivity, and a possible prognostic value. Amyotroph Lateral Scler. 2011;12:140\u20133.","journal-title":"Amyotroph Lateral Scler"},{"key":"867_CR331","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00401-008-0456-1","volume":"117","author":"T Kasai","year":"2009","unstructured":"Kasai T, Tokuda T, Ishigami N, Sasayama H, Foulds P, Mitchell DJ, Mann DM, Allsop D, Nakagawa M. Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neuropathol. 2009;117:55\u201362.","journal-title":"Acta Neuropathol"},{"key":"867_CR332","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12883-018-1091-7","volume":"18","author":"V Majumder","year":"2018","unstructured":"Majumder V, Gregory JM, Barria MA, Green A, Pal S. TDP-43 as a potential biomarker for amyotrophic lateral sclerosis: a systematic review and meta-analysis. BMC Neurol. 2018;18:90.","journal-title":"BMC Neurol"},{"key":"867_CR333","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13024-023-00685-6","volume":"19","author":"KE Irwin","year":"2024","unstructured":"Irwin KE, Sheth U, Wong PC, Gendron TF. Fluid biomarkers for amyotrophic lateral sclerosis: a review. Mol Neurodegener. 2024;19:9.","journal-title":"Mol Neurodegener"},{"key":"867_CR334","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1126\/science.aab0983","volume":"349","author":"JP Ling","year":"2015","unstructured":"Ling JP, Pletnikova O, Troncoso JC, Wong PC. TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science. 2015;349:650\u20135.","journal-title":"Science"},{"key":"867_CR335","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13024-023-00608-5","volume":"18","author":"PR Mehta","year":"2023","unstructured":"Mehta PR, Brown AL, Ward ME, Fratta P. The era of cryptic exons: implications for ALS-FTD. Mol Neurodegener. 2023;18:16.","journal-title":"Mol Neurodegener"},{"key":"867_CR336","doi-asserted-by":"publisher","first-page":"eadg7162","DOI":"10.1126\/scitranslmed.adg7162","volume":"16","author":"S Seddighi","year":"2024","unstructured":"Seddighi S, Qi YA, Brown AL, Wilkins OG, Bereda C, Belair C, Zhang YJ, Prudencio M, Keuss MJ, Khandeshi A, et al. Mis-spliced transcripts generate de novo proteins in TDP-43-related ALS\/FTD. Sci Transl Med. 2024;16:eadg7162.","journal-title":"Sci Transl Med"},{"key":"867_CR337","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13024-024-00718-8","volume":"19","author":"A Calliari","year":"2024","unstructured":"Calliari A, Daughrity LM, Albagli EA, Castellanos Otero P, Yue M, Jansen-West K, Islam NN, Caulfield T, Rawlinson B, DeTure M, et al. HDGFL2 cryptic proteins report presence of TDP-43 pathology in neurodegenerative diseases. Mol Neurodegener. 2024;19:29.","journal-title":"Mol Neurodegener"},{"key":"867_CR338","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1038\/s41591-023-02476-4","volume":"29","author":"ECB Johnson","year":"2023","unstructured":"Johnson ECB, Bian S, Haque RU, Carter EK, Watson CM, Gordon BA, Ping L, Duong DM, Epstein MP, McDade E, et al. Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer\u2019s disease. Nat Med. 2023;29:1979\u201388.","journal-title":"Nat Med"},{"key":"867_CR339","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/ana.25682","volume":"87","author":"D Matuskey","year":"2020","unstructured":"Matuskey D, Tinaz S, Wilcox KC, Naganawa M, Toyonaga T, Dias M, Henry S, Pittman B, Ropchan J, Nabulsi N, et al. Synaptic Changes in Parkinson Disease Assessed with in vivo Imaging. Ann Neurol. 2020;87:329\u201338.","journal-title":"Ann Neurol"},{"key":"867_CR340","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1002\/alz.12097","volume":"16","author":"AP Mecca","year":"2020","unstructured":"Mecca AP, Chen MK, O\u2019Dell RS, Naganawa M, Toyonaga T, Godek TA, Harris JE, Bartlett HH, Zhao W, Nabulsi NB, et al. In vivo measurement of widespread synaptic loss in Alzheimer\u2019s disease with SV2A PET. Alzheimers Dement. 2020;16:974\u201382.","journal-title":"Alzheimers Dement"},{"key":"867_CR341","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","volume":"27","author":"O Hansson","year":"2021","unstructured":"Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27:954\u201363.","journal-title":"Nat Med"},{"key":"867_CR342","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/0896-6273(88)90197-3","volume":"1","author":"SC Ng","year":"1988","unstructured":"Ng SC, de la Monte SM, Conboy GL, Karns LR, Fishman MC. Cloning of human GAP-43: growth association and ischemic resurgence. Neuron. 1988;1:133\u20139.","journal-title":"Neuron"},{"key":"867_CR343","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.1523\/JNEUROSCI.10-12-03782.1990","volume":"10","author":"A Represa","year":"1990","unstructured":"Represa A, Deloulme JC, Sensenbrenner M, Ben-Ari Y, Baudier J. Neurogranin: immunocytochemical localization of a brain-specific protein kinase C substrate. J Neurosci. 1990;10:3782\u201392.","journal-title":"J Neurosci"},{"key":"867_CR344","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006189","volume":"1","author":"A Serrano-Pozo","year":"2011","unstructured":"Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1: a006189.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"867_CR345","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41582-018-0072-1","volume":"14","author":"TK Ulland","year":"2018","unstructured":"Ulland TK, Colonna M. TREM2 - a key player in microglial biology and Alzheimer disease. Nat Rev Neurol. 2018;14:667\u201375.","journal-title":"Nat Rev Neurol"},{"key":"867_CR346","doi-asserted-by":"crossref","unstructured":"Gratuze M, Chen Y, Parhizkar S, Jain N, Strickland MR, Serrano JR, Colonna M, Ulrich JD, Holtzman DM: Activated microglia mitigate A\u03b2-associated tau seeding and spreading. J Exp Med. 2021;218:e20210542.","DOI":"10.1084\/jem.20210542"},{"key":"867_CR347","doi-asserted-by":"publisher","first-page":"15318","DOI":"10.1038\/s41598-024-66211-w","volume":"14","author":"F Nabizadeh","year":"2024","unstructured":"Nabizadeh F, Seyedmirzaei H, Karami S. Neuroimaging biomarkers and CSF sTREM2 levels in Alzheimer\u2019s disease: a longitudinal study. Sci Rep. 2024;14:15318.","journal-title":"Sci Rep"},{"key":"867_CR348","doi-asserted-by":"publisher","first-page":"4001","DOI":"10.1038\/s41467-021-24220-7","volume":"12","author":"WT Hu","year":"2021","unstructured":"Hu WT, Ozturk T, Kollhoff A, Wharton W, Christina Howell J. Higher CSF sTNFR1-related proteins associate with better prognosis in very early Alzheimer\u2019s disease. Nat Commun. 2021;12:4001.","journal-title":"Nat Commun"},{"key":"867_CR349","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S1474-4422(23)00247-8","volume":"22","author":"K Schlepckow","year":"2023","unstructured":"Schlepckow K, Morenas-Rodr\u00edguez E, Hong S, Haass C. Stimulation of TREM2 with agonistic antibodies-an emerging therapeutic option for Alzheimer\u2019s disease. The Lancet Neurology. 2023;22:1048\u201360.","journal-title":"The Lancet Neurology"},{"key":"867_CR350","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2023.137277","volume":"807","author":"X Zhang","year":"2023","unstructured":"Zhang X, Zhong X, Wang L, Li H, Yang L, Li X, Yu X, Xie A. Effects of soluble TREM2 on motor progression in Parkinson\u2019s disease. Neurosci Lett. 2023;807: 137277.","journal-title":"Neurosci Lett"},{"key":"867_CR351","doi-asserted-by":"publisher","first-page":"1515252","DOI":"10.3389\/fneur.2024.1515252","volume":"15","author":"L Jiao","year":"2024","unstructured":"Jiao L, Yang J, Wang W, Liu X, Fu Y, Fan D. sTREM2 cerebrospinal fluid levels are a potential biomarker in amyotrophic lateral sclerosis and associate with UMN burden. Front Neurol. 2024;15:1515252.","journal-title":"Front Neurol"},{"key":"867_CR352","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.neurobiolaging.2019.12.012","volume":"88","author":"L Batzu","year":"2020","unstructured":"Batzu L, Westman E, Pereira JB. Cerebrospinal fluid progranulin is associated with increased cortical thickness in early stages of Alzheimer\u2019s disease. Neurobiol Aging. 2020;88:61\u201370.","journal-title":"Neurobiol Aging"},{"key":"867_CR353","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3233\/JAD-150746","volume":"50","author":"E Morenas-Rodriguez","year":"2016","unstructured":"Morenas-Rodriguez E, Cervera-Carles L, Vilaplana E, Alcolea D, Carmona-Iragui M, Dols-Icardo O, Ribosa-Nogue R, Munoz-Llahuna L, Sala I, Belen Sanchez-Saudinos M, et al. Progranulin Protein Levels in Cerebrospinal Fluid in Primary Neurodegenerative Dementias. J Alzheimers Dis. 2016;50:539\u201346.","journal-title":"J Alzheimers Dis"},{"key":"867_CR354","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1097\/NEN.0b013e3181fc9aea","volume":"69","author":"T Philips","year":"2010","unstructured":"Philips T, De Muynck L, Thu HN, Weynants B, Vanacker P, Dhondt J, Sleegers K, Schelhaas HJ, Verbeek M, Vandenberghe R, et al. Microglial upregulation of progranulin as a marker of motor neuron degeneration. J Neuropathol Exp Neurol. 2010;69:1191\u2013200.","journal-title":"J Neuropathol Exp Neurol"},{"key":"867_CR355","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3389\/fnins.2018.00609","volume":"12","author":"JR Perea","year":"2018","unstructured":"Perea JR, Lleo A, Alcolea D, Fortea J, Avila J, Bolos M. Decreased CX3CL1 Levels in the Cerebrospinal Fluid of Patients With Alzheimer\u2019s Disease. Front Neurosci. 2018;12:609.","journal-title":"Front Neurosci"},{"key":"867_CR356","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13024-017-0226-4","volume":"12","author":"F Llorens","year":"2017","unstructured":"Llorens F, Thune K, Tahir W, Kanata E, Diaz-Lucena D, Xanthopoulos K, Kovatsi E, Pleschka C, Garcia-Esparcia P, Schmitz M, et al. YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias. Mol Neurodegener. 2017;12:83.","journal-title":"Mol Neurodegener"},{"key":"867_CR357","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1080\/14789450.2019.1628643","volume":"16","author":"F Baldacci","year":"2019","unstructured":"Baldacci F, Lista S, Palermo G, Giorgi FS, Vergallo A, Hampel H. The neuroinflammatory biomarker YKL-40 for neurodegenerative diseases: advances in development. Expert Rev Proteomics. 2019;16:593\u2013600.","journal-title":"Expert Rev Proteomics"},{"key":"867_CR358","doi-asserted-by":"crossref","unstructured":"Pinteac R, Montalban X, Comabella M: Chitinases and chitinase-like proteins as biomarkers in neurologic disorders. Neurol Neuroimmunol Neuroinflamm 2021;8:e921.","DOI":"10.1212\/NXI.0000000000000921"},{"key":"867_CR359","doi-asserted-by":"crossref","unstructured":"Russo C, Valle MS, Casabona A, Malaguarnera L. Chitinase Signature in the Plasticity of Neurodegenerative Diseases. Int J Mol Sci 2023;24:6301.","DOI":"10.3390\/ijms24076301"},{"key":"867_CR360","doi-asserted-by":"publisher","first-page":"5013","DOI":"10.1038\/s41467-024-49312-y","volume":"15","author":"J Belien","year":"2024","unstructured":"Belien J, Swinnen S, D\u2019Hondt R. Verdu de Juan L, Dedoncker N, Matthys P, Bauer J, Vens C, Moylett S, Dubois B: CHIT1 at diagnosis predicts faster disability progression and reflects early microglial activation in multiple sclerosis. Nat Commun. 2024;15:5013.","journal-title":"Nat Commun"},{"key":"867_CR361","doi-asserted-by":"publisher","first-page":"5167","DOI":"10.1007\/s12035-017-0707-z","volume":"55","author":"KM Budge","year":"2018","unstructured":"Budge KM, Neal ML, Richardson JR, Safadi FF. Glycoprotein NMB: an Emerging Role in Neurodegenerative Disease. Mol Neurobiol. 2018;55:5167\u201376.","journal-title":"Mol Neurobiol"},{"key":"867_CR362","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s40478-018-0612-3","volume":"6","author":"M Huttenrauch","year":"2018","unstructured":"Huttenrauch M, Ogorek I, Klafki H, Otto M, Stadelmann C, Weggen S, Wiltfang J, Wirths O. Glycoprotein NMB: a novel Alzheimer\u2019s disease associated marker expressed in a subset of activated microglia. Acta Neuropathol Commun. 2018;6:108.","journal-title":"Acta Neuropathol Commun"},{"key":"867_CR363","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1177\/1877718X241288712","volume":"14","author":"XC Zhu","year":"2024","unstructured":"Zhu XC, Mizutani Y, Ohdake R, Tatebe H, Maeda T, Shima S, Ueda A, Ito M, Ito S, Tokuda T, Watanabe H. CSF GPNMB in Parkinson\u2019s disease: A potential association with age and microglial activation. J Parkinsons Dis. 2024;14:1533\u201342.","journal-title":"J Parkinsons Dis"},{"key":"867_CR364","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1002\/alz.12756","volume":"18","author":"O Hansson","year":"2022","unstructured":"Hansson O, Edelmayer RM, Boxer AL, Carrillo MC, Mielke MM, Rabinovici GD, Salloway S, Sperling R, Zetterberg H, Teunissen CE. The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease. Alzheimers Dement. 2022;18:2669\u201386.","journal-title":"Alzheimers Dement"},{"key":"867_CR365","first-page":"1","volume":"51","author":"DK Kim","year":"2019","unstructured":"Kim DK, Han D, Park J, Choi H, Park JC, Cha MY, Woo J, Byun MS, Lee DY, Kim Y, Mook-Jung I. Deep proteome profiling of the hippocampus in the 5XFAD mouse model reveals biological process alterations and a novel biomarker of Alzheimer\u2019s disease. Exp Mol Med. 2019;51:1\u201317.","journal-title":"Exp Mol Med"},{"key":"867_CR366","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.pharmthera.2018.03.002","volume":"188","author":"B Shafit-Zagardo","year":"2018","unstructured":"Shafit-Zagardo B, Gruber RC, DuBois JC. The role of TAM family receptors and ligands in the nervous system: From development to pathobiology. Pharmacol Ther. 2018;188:97\u2013117.","journal-title":"Pharmacol Ther"},{"key":"867_CR367","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.700959","volume":"13","author":"L Li","year":"2021","unstructured":"Li L, Ren J, Pan C, Li Y, Xu J, Dong H, Chen Y, Liu W. Serum miR-214 Serves as a Biomarker for Prodromal Parkinson\u2019s Disease. Front Aging Neurosci. 2021;13: 700959.","journal-title":"Front Aging Neurosci"},{"key":"867_CR368","doi-asserted-by":"publisher","first-page":"6592139","DOI":"10.1155\/2017\/6592139","volume":"2017","author":"B Largeau","year":"2017","unstructured":"Largeau B, Dupont AC, Guilloteau D, Santiago-Ribeiro MJ, Arlicot N. TSPO PET Imaging: From Microglial Activation to Peripheral Sterile Inflammatory Diseases? Contrast Media Mol Imaging. 2017;2017:6592139.","journal-title":"Contrast Media Mol Imaging"},{"key":"867_CR369","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.bbi.2023.07.023","volume":"113","author":"LJ De Picker","year":"2023","unstructured":"De Picker LJ, Morrens M, Branchi I, Haarman BCM, Terada T, Kang MS, Boche D, Tremblay ME, Leroy C, Bottlaender M, Ottoy J. TSPO PET brain inflammation imaging: A transdiagnostic systematic review and meta-analysis of 156 case-control studies. Brain Behav Immun. 2023;113:415\u201331.","journal-title":"Brain Behav Immun"},{"key":"867_CR370","doi-asserted-by":"publisher","first-page":"e1331","DOI":"10.1212\/WNL.0000000000007133","volume":"92","author":"GD Femminella","year":"2019","unstructured":"Femminella GD, Dani M, Wood M, Fan Z, Calsolaro V, Atkinson R, Edginton T, Hinz R, Brooks DJ, Edison P. Microglial activation in early Alzheimer trajectory is associated with higher gray matter volume. Neurology. 2019;92:e1331\u201343.","journal-title":"Neurology"},{"key":"867_CR371","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1073\/pnas.1812155116","volume":"116","author":"AG Horti","year":"2019","unstructured":"Horti AG, Naik R, Foss CA, Minn I, Misheneva V, Du Y, Wang Y, Mathews WB, Wu Y, Hall A, et al. PET imaging of microglia by targeting macrophage colony-stimulating factor 1 receptor (CSF1R). Proc Natl Acad Sci U S A. 2019;116:1686\u201391.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"867_CR372","doi-asserted-by":"crossref","unstructured":"Mills KA, Du Y, Coughlin JM, Foss CA, Horti AG, Jenkins KR, Skorobogatova Y, Spiro E, Motley CS, Dannals RF, et al. Exploring [11C]CPPC as a CSF1R-targeted PET imaging marker for early Parkinson\u2019s disease severity. J Clin Invest. 2025;15;135(12):e186591.","DOI":"10.1172\/JCI186591"},{"key":"867_CR373","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ejphar.2006.05.025","volume":"542","author":"K Kim","year":"2006","unstructured":"Kim K, Moore DH, Makriyannis A, Abood ME. AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur J Pharmacol. 2006;542:100\u20135.","journal-title":"Eur J Pharmacol"},{"key":"867_CR374","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41401-018-0035-5","volume":"40","author":"R Ni","year":"2019","unstructured":"Ni R, Mu L, Ametamey S. Positron emission tomography of type 2 cannabinoid receptors for detecting inflammation in the central nervous system. Acta Pharmacol Sin. 2019;40:351\u20137.","journal-title":"Acta Pharmacol Sin"},{"key":"867_CR375","doi-asserted-by":"publisher","first-page":"4465","DOI":"10.1021\/acschemneuro.1c00641","volume":"12","author":"B van der Wildt","year":"2021","unstructured":"van der Wildt B, Janssen B, Pekosak A, Steen EJL, Schuit RC, Kooijman EJM, Beaino W, Vugts DJ, Windhorst AD. Novel Thienopyrimidine-Based PET Tracers for P2Y(12) Receptor Imaging in the Brain. ACS Chem Neurosci. 2021;12:4465\u201374.","journal-title":"ACS Chem Neurosci"},{"key":"867_CR376","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.739130","volume":"12","author":"R Zhou","year":"2021","unstructured":"Zhou R, Ji B, Kong Y, Qin L, Ren W, Guan Y, Ni R. PET Imaging of Neuroinflammation in Alzheimer\u2019s Disease. Front Immunol. 2021;12: 739130.","journal-title":"Front Immunol"},{"key":"867_CR377","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings J, Apostolova L, Rabinovici GD, Atri A, Aisen P, Greenberg S, Hendrix S, Selkoe D, Weiner M, Petersen RC, Salloway S. Lecanemab: Appropriate use recommendations. J Prev Alzheimers Dis. 2023;10:362\u201377.","journal-title":"J Prev Alzheimers Dis"},{"key":"867_CR378","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1021\/acschemneuro.8b00334","volume":"9","author":"DM Angelova","year":"2018","unstructured":"Angelova DM, Brown DR. Altered Processing of beta-Amyloid in SH-SY5Y Cells Induced by Model Senescent Microglia. ACS Chem Neurosci. 2018;9:3137\u201352.","journal-title":"ACS Chem Neurosci"},{"key":"867_CR379","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1016\/j.neurobiolaging.2015.05.022","volume":"36","author":"MM Zeineh","year":"2015","unstructured":"Zeineh MM, Chen Y, Kitzler HH, Hammond R, Vogel H, Rutt BK. Activated iron-containing microglia in the human hippocampus identified by magnetic resonance imaging in Alzheimer disease. Neurobiol Aging. 2015;36:2483\u2013500.","journal-title":"Neurobiol Aging"},{"key":"867_CR380","doi-asserted-by":"publisher","first-page":"13874","DOI":"10.1038\/s41598-019-50432-5","volume":"9","author":"M Taquet","year":"2019","unstructured":"Taquet M, Jankovski A, Rensonnet G, Jacobs D. des Rieux A, Macq B, Warfield SK, Scherrer B: Extra-axonal restricted diffusion as an in-vivo marker of reactive microglia. Sci Rep. 2019;9:13874.","journal-title":"Sci Rep"},{"key":"867_CR381","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3389\/fnins.2019.00081","volume":"13","author":"SY Yi","year":"2019","unstructured":"Yi SY, Barnett BR, Torres-Velazquez M, Zhang Y, Hurley SA, Rowley PA, Hernando D, Yu JJ. Detecting Microglial Density With Quantitative Multi-Compartment Diffusion MRI. Front Neurosci. 2019;13:81.","journal-title":"Front Neurosci"},{"key":"867_CR382","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1002\/alz.12342","volume":"17","author":"DG Morgan","year":"2021","unstructured":"Morgan DG, Mielke MM. Knowledge gaps in Alzheimer\u2019s disease immune biomarker research. Alzheimers Dement. 2021;17:2030\u201342.","journal-title":"Alzheimers Dement"},{"key":"867_CR383","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/s41593-018-0236-8","volume":"21","author":"TM Dawson","year":"2018","unstructured":"Dawson TM, Golde TE, Lagier-Tourenne C. Animal models of neurodegenerative diseases. Nat Neurosci. 2018;21:1370\u20139.","journal-title":"Nat Neurosci"},{"issue":"1016\u20131033","key":"867_CR384","volume":"103","author":"J Hasselmann","year":"2019","unstructured":"Hasselmann J, Coburn MA, England W, Figueroa Velez DX, Kiani Shabestari S, Tu CH, McQuade A, Kolahdouzan M, Echeverria K, Claes C, et al. Development of a Chimeric Model to Study and Manipulate Human Microglia In Vivo. Neuron. 2019;103(1016\u20131033): e1010.","journal-title":"Neuron"},{"key":"867_CR385","doi-asserted-by":"crossref","unstructured":"Abels ER, Nieland L, Hickman S, Broekman MLD, El Khoury J, Maas SLN: Comparative Analysis Identifies Similarities between the Human and Murine Microglial Sensomes. Int J Mol Sci 2021;22:1495.","DOI":"10.3390\/ijms22031495"},{"key":"867_CR386","doi-asserted-by":"publisher","first-page":"6129","DOI":"10.1038\/s41467-020-19737-2","volume":"11","author":"M Olah","year":"2020","unstructured":"Olah M, Menon V, Habib N, Taga MF, Ma Y, Yung CJ, Cimpean M, Khairallah A, Coronas-Samano G, Sankowski R, et al. Single cell RNA sequencing of human microglia uncovers a subset associated with Alzheimer\u2019s disease. Nat Commun. 2020;11:6129.","journal-title":"Nat Commun"},{"key":"867_CR387","first-page":"430","volume":"26","author":"H Zeng","year":"2023","unstructured":"Zeng H, Huang J, Zhou H, Meilandt WJ, Dejanovic B, Zhou Y, Bohlen CJ, Lee SH, Ren J, Liu A, et al. Integrative in situ mapping of single-cell transcriptional states and tissue histopathology in a mouse model of Alzheimer\u2019s disease. Nat Neurosci. 2023;26:430\u201346.","journal-title":"Nat Neurosci"},{"key":"867_CR388","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1038\/s12276-023-01123-9","volume":"55","author":"H Choi","year":"2023","unstructured":"Choi H, Lee EJ, Shin JS, Kim H, Bae S, Choi Y, Lee DS. Spatiotemporal characterization of glial cell activation in an Alzheimer\u2019s disease model by spatially resolved transcriptomics. Exp Mol Med. 2023;55:2564\u201375.","journal-title":"Exp Mol Med"},{"key":"867_CR389","doi-asserted-by":"crossref","unstructured":"Abdullahi Tunde Aborode a OAEb, Isreal Ayobami Onifade c, Emmanuel Olotu d, Oche Joseph Otorkpa e, Qasim Mehmood f, Suliat Iyabode Abdulai g, Abdullahi Jamiu h, Abraham Osinuga i, Christian Inya Oko j, Sodiq Fakorede k, Mustapha Mangdow k, Oloyede Babatunde l, Zainab Olapade m, Awolola Gbonjubola Victoria n, Abosede Salami o, Idowu A. Usman p, Victor Ifechukwude Agboli p, Ridwan Olamilekan Adesola q: The role of machine learning in discovering biomarkers and predicting treatment strategies for neurodegenerative diseases: A narrative review. NeuroMarkers 2025;2.","DOI":"10.1016\/j.neumar.2024.100034"},{"key":"867_CR390","doi-asserted-by":"publisher","DOI":"10.1016\/j.sbi.2024.102857","volume":"87","author":"F Angelucci","year":"2024","unstructured":"Angelucci F, Ai AR, Piendel L, Cerman J, Hort J. Integrating AI in fighting advancing Alzheimer: diagnosis, prevention, treatment, monitoring, mechanisms, and clinical trials. Curr Opin Struct Biol. 2024;87:102857.","journal-title":"Curr Opin Struct Biol"},{"key":"867_CR391","doi-asserted-by":"publisher","first-page":"548","DOI":"10.3988\/jcn.2024.0288","volume":"20","author":"J Cecot","year":"2024","unstructured":"Cecot J, Zarzecki K, Mandryk M. Potential Benefits of Using Artificial Intelligence to Diagnose Alzheimer\u2019s Disease. J Clin Neurol. 2024;20:548\u20139.","journal-title":"J Clin Neurol"},{"key":"867_CR392","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.celrep.2017.12.066","volume":"22","author":"BA Friedman","year":"2018","unstructured":"Friedman BA, Srinivasan K, Ayalon G, Meilandt WJ, Lin H, Huntley MA, Cao Y, Lee SH, Haddick PCG, Ngu H, et al. Diverse Brain Myeloid Expression Profiles Reveal Distinct Microglial Activation States and Aspects of Alzheimer\u2019s Disease Not Evident in Mouse Models. Cell Rep. 2018;22:832\u201347.","journal-title":"Cell Rep"},{"key":"867_CR393","doi-asserted-by":"crossref","unstructured":"Gosselin D, Skola D, Coufal NG, Holtman IR, Schlachetzki JCM, Sajti E, Jaeger BN, O\u2019Connor C, Fitzpatrick C, Pasillas MP, et al: An environment-dependent transcriptional network specifies human microglia identity. Science 2017;356:eaal3222.","DOI":"10.1126\/science.aal3222"},{"issue":"1609\u20131622","key":"867_CR394","volume":"179","author":"L Geirsdottir","year":"2019","unstructured":"Geirsdottir L, David E, Keren-Shaul H, Weiner A, Bohlen SC, Neuber J, Balic A, Giladi A, Sheban F, Dutertre CA, et al. Cross-Species Single-Cell Analysis Reveals Divergence of the Primate Microglia Program. Cell. 2019;179(1609\u20131622): e1616.","journal-title":"Cell"},{"key":"867_CR395","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13024-019-0347-z","volume":"14","author":"AM Speicher","year":"2019","unstructured":"Speicher AM, Wiendl H, Meuth SG, Pawlowski M. Generating microglia from human pluripotent stem cells: novel in vitro models for the study of neurodegeneration. Mol Neurodegener. 2019;14:46.","journal-title":"Mol Neurodegener"},{"key":"867_CR396","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41380-019-0468-3","volume":"25","author":"J Penney","year":"2020","unstructured":"Penney J, Ralvenius WT, Tsai LH. Modeling Alzheimer\u2019s disease with iPSC-derived brain cells. Mol Psychiatry. 2020;25:148\u201367.","journal-title":"Mol Psychiatry"},{"key":"867_CR397","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41380-022-01892-1","volume":"28","author":"W Zhang","year":"2023","unstructured":"Zhang W, Jiang J, Xu Z, Yan H, Tang B, Liu C, Chen C, Meng Q. Microglia-containing human brain organoids for the study of brain development and pathology. Mol Psychiatry. 2023;28:96\u2013107.","journal-title":"Mol Psychiatry"},{"issue":"2153\u20132166","key":"867_CR398","volume":"28","author":"G Popova","year":"2021","unstructured":"Popova G, Soliman SS, Kim CN, Keefe MG, Hennick KM, Jain S, Li T, Tejera D, Shin D, Chhun BB, et al. Human microglia states are conserved across experimental models and regulate neural stem cell responses in chimeric organoids. Cell Stem Cell. 2021;28(2153\u20132166): e2156.","journal-title":"Cell Stem Cell"},{"issue":"1276\u20131290","key":"867_CR399","volume":"169","author":"H Keren-Shaul","year":"2017","unstructured":"Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, David E, Baruch K, Lara-Astaiso D, Toth B, et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer\u2019s Disease. Cell. 2017;169(1276\u20131290): e1217.","journal-title":"Cell"},{"key":"867_CR400","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1474-4422(18)30028-0","volume":"17","author":"BA Gordon","year":"2018","unstructured":"Gordon BA, Blazey TM, Su Y, Hari-Raj A, Dincer A, Flores S, Christensen J, McDade E, Wang G, Xiong C, et al. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer\u2019s disease: a longitudinal study. Lancet Neurol. 2018;17:241\u201350.","journal-title":"Lancet Neurol"},{"key":"867_CR401","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1038\/s41598-025-88134-w","volume":"15","author":"Z Xie","year":"2025","unstructured":"Xie Z, Situ Y, Deng L, Liang M, Ding H, Guo Z, Xu Q, Liang Z, Shao Z. Identification of therapeutic targets for Alzheimer\u2019s Disease Treatment using bioinformatics and machine learning. Sci Rep. 2025;15:3888.","journal-title":"Sci Rep"},{"key":"867_CR402","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.70166","volume":"13","author":"P Liang","year":"2025","unstructured":"Liang P, Wang Y, Liu J, Huang H, Li Y, Kang J, Li G, Wu H. Identification and Exploration of Immunity-Related Genes and Natural Products for Alzheimer\u2019s Disease Based on Bioinformatics, Molecular Docking, and Molecular Dynamics. Immun Inflamm Dis. 2025;13: e70166.","journal-title":"Immun Inflamm Dis"},{"key":"867_CR403","doi-asserted-by":"crossref","unstructured":"Chudzik A, Sledzianowski A, Przybyszewski AW: Machine Learning and Digital Biomarkers Can Detect Early Stages of Neurodegenerative Diseases. Sensors (Basel) 2024;24:1572.","DOI":"10.3390\/s24051572"},{"key":"867_CR404","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14591","volume":"21","author":"M Menendez-Gonzalez","year":"2025","unstructured":"Menendez-Gonzalez M. Implementing a tridimensional diagnostic framework for personalized medicine in neurodegenerative diseases. Alzheimers Dement. 2025;21: e14591.","journal-title":"Alzheimers Dement"},{"key":"867_CR405","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00702-021-02449-2","volume":"129","author":"KA Jellinger","year":"2022","unstructured":"Jellinger KA. Recent update on the heterogeneity of the Alzheimer\u2019s disease spectrum. J Neural Transm (Vienna). 2022;129:1\u201324.","journal-title":"J Neural Transm (Vienna)"},{"key":"867_CR406","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/s41591-021-01348-z","volume":"27","author":"S Palmqvist","year":"2021","unstructured":"Palmqvist S, Tideman P, Cullen N, Zetterberg H, Blennow K. Alzheimer\u2019s Disease Neuroimaging I, Dage JL, Stomrud E, Janelidze S, Mattsson-Carlgren N, Hansson O: Prediction of future Alzheimer\u2019s disease dementia using plasma phospho-tau combined with other accessible measures. Nat Med. 2021;27:1034\u201342.","journal-title":"Nat Med"},{"key":"867_CR407","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s10286-024-01035-2","volume":"34","author":"R Isonaka","year":"2024","unstructured":"Isonaka R, Sullivan P, Holmes C, Goldstein DS. A pathophysiological biomarker combination separates Lewy body from non-Lewy body neurogenic orthostatic hypotension \u200b. Clin Auton Res. 2024;34:329\u201339.","journal-title":"Clin Auton Res"},{"key":"867_CR408","doi-asserted-by":"crossref","unstructured":"Goldstein DS, Holmes C, Sullivan P, Lopez G, Gelsomino J, Moore S, Isonaka R, Wu T, Sharabi Y: Cardiac noradrenergic deficiency revealed by 18F-dopamine positron emission tomography identifies preclinical central Lewy body diseases. J Clin Invest 2024;134:e172460.","DOI":"10.1172\/JCI172460"},{"key":"867_CR409","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40035-020-00221-2","volume":"9","author":"HS Kwon","year":"2020","unstructured":"Kwon HS, Koh SH. Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Transl Neurodegener. 2020;9:42.","journal-title":"Transl Neurodegener"},{"key":"867_CR410","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41582-020-00435-y","volume":"17","author":"F Leng","year":"2021","unstructured":"Leng F, Edison P. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat Rev Neurol. 2021;17:157\u201372.","journal-title":"Nat Rev Neurol"},{"key":"867_CR411","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000210248","volume":"104","author":"A Morotti","year":"2025","unstructured":"Morotti A, Pilotto A, Zanola D, Galli A, Caratozzolo S, Gasparotti R, Padovani A. Cerebral Amyloid Angiopathy in Alzheimer Disease: A Comparison Between Different Versions of the Boston Criteria. Neurology. 2025;104: e210248.","journal-title":"Neurology"},{"key":"867_CR412","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13024-025-00822-3","volume":"20","author":"N Franzmeier","year":"2025","unstructured":"Franzmeier N, Roemer-Cassiano SN, Bernhardt AM, Dehsarvi A, Dewenter A, Steward A, Biel D, Frontzkowski L, Zhu Z, Gnorich J, et al. Alpha synuclein co-pathology is associated with accelerated amyloid-driven tau accumulation in Alzheimer\u2019s disease. Mol Neurodegener. 2025;20:31.","journal-title":"Mol Neurodegener"},{"key":"867_CR413","unstructured":"Sheena M. Posey Norris R, Eva Childers, Rapporteur, and Sarah Carter: Multimodal Biomarkers for Central Nervous System Disorders National Academies Forum on Neuroscience and Nervous System Disorders; 2023."},{"key":"867_CR414","doi-asserted-by":"publisher","first-page":"1345417","DOI":"10.3389\/fnagi.2024.1345417","volume":"16","author":"M Mehdipour Ghazi","year":"2024","unstructured":"Mehdipour Ghazi M, Selnes P, Timon-Reina S, Tecelao S, Ingala S, Bjornerud A, Kirsebom BE, Fladby T, Nielsen M. Comparative analysis of multimodal biomarkers for amyloid-beta positivity detection in Alzheimer\u2019s disease cohorts. Front Aging Neurosci. 2024;16:1345417.","journal-title":"Front Aging Neurosci"},{"key":"867_CR415","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13195-024-01668-5","volume":"17","author":"S Ravichandran","year":"2025","unstructured":"Ravichandran S, Snyder PJ, Alber J, Murchison CF, Chaby LE, Jeromin A, Arthur E. Association and multimodal model of retinal and blood-based biomarkers for detection of preclinical Alzheimer\u2019s disease. Alzheimers Res Ther. 2025;17:19.","journal-title":"Alzheimers Res Ther"},{"key":"867_CR416","unstructured":"Companion Diagnostics Explained: Their Critical Role in Cancer Care and Our Latest Approvals (https:\/\/www.foundationmedicine.com\/blog\/companion-diagnostics-explained-their-critical-role-cancer-care-and-our-latest-approvals)."},{"key":"867_CR417","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1093\/brain\/awad059","volume":"146","author":"JL Robinson","year":"2023","unstructured":"Robinson JL, Xie SX, Baer DR, Suh E, Van Deerlin VM, Loh NJ, Irwin DJ, McMillan CT, Wolk DA, Chen-Plotkin A, et al. Pathological combinations in neurodegenerative disease are heterogeneous and disease-associated. Brain. 2023;146:2557\u201369.","journal-title":"Brain"},{"key":"867_CR418","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/s41398-024-03121-5","volume":"14","author":"J Wen","year":"2024","unstructured":"Wen J, Yang Z, Nasrallah IM, Cui Y, Erus G, Srinivasan D, Abdulkadir A, Mamourian E, Hwang G, Singh A, et al. Genetic and clinical correlates of two neuroanatomical AI dimensions in the Alzheimer\u2019s disease continuum. Transl Psychiatry. 2024;14:420.","journal-title":"Transl Psychiatry"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00867-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-025-00867-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00867-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T05:46:14Z","timestamp":1757223974000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-025-00867-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":418,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["867"],"URL":"https:\/\/doi.org\/10.1186\/s13024-025-00867-4","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"assertion":[{"value":"9 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"82"}}